Array ( [0] => {{short description|Group of endocrine diseases characterized by high blood sugar levels}} [1] => {{About|the common insulin disorder|the urine hyper-production disorder|Diabetes insipidus|other uses|Diabetes (disambiguation)}} [2] => {{pp-pc|small=yes}} [3] => {{use American English|date=January 2023}} [4] => {{Infobox medical condition (new) [5] => | name = Diabetes mellitus [6] => | pronounce = {{IPAc-en|ˌ|d|aɪ|_|ə|'|b|i|_|t|i|z|,_|-|t|I|s}} [7] => | image = Blue circle for diabetes.svg [8] => | image_size = 250px [9] => | alt = A hollow circle with a thick blue border and a clear centre [10] => | caption = Universal blue circle symbol for diabetes{{cite web|title=Diabetes Blue Circle Symbol |url=http://www.diabetesbluecircle.org |date=17 March 2006 |publisher=International Diabetes Federation |url-status=dead |archive-url=https://web.archive.org/web/20070805042346/http://www.diabetesbluecircle.org/ |archive-date=5 August 2007 }} [11] => | field = [[Endocrinology]] [12] => | symptoms = {{Plainlist| [13] => * [[polyuria|Frequent urination]] [14] => * [[polydipsia|Increased thirst]] [15] => * [[polyphagia|Increased hunger]] [16] => }} [17] => | complications = {{Plainlist| [18] => * Metabolic imbalances [19] => * Cardiovascular diseases [20] => * Nerve and brain damage [21] => * Kidney failure [22] => * Gastrointestinal changes{{cite web |title=Diabetes |url=https://www.who.int/news-room/fact-sheets/detail/diabetes |website=www.who.int |access-date=1 October 2022 |archive-date=26 February 2023 |archive-url=https://web.archive.org/web/20230226173058/https://www.who.int/news-room/fact-sheets/detail/diabetes |url-status=live }}{{cite journal | vauthors = Krishnasamy S, Abell TL | title = Diabetic Gastroparesis: Principles and Current Trends in Management | journal = Diabetes Therapy | volume = 9 | issue = Suppl 1 | pages = 1–42 | date = July 2018 | pmid = 29934758 | pmc = 6028327 | doi = 10.1007/s13300-018-0454-9 }}{{cite journal | vauthors = Saedi E, Gheini MR, Faiz F, Arami MA | title = Diabetes mellitus and cognitive impairments | journal = World Journal of Diabetes | volume = 7 | issue = 17 | pages = 412–422 | date = September 2016 | pmid = 27660698 | pmc = 5027005 | doi = 10.4239/wjd.v7.i17.412 | doi-access = free }} [23] => }} [24] => | duration = Remission may occur, but diabetes is often life-long [25] => | types = {{Plainlist| [26] => * Type 1 diabetes [27] => * Type 2 diabetes [28] => * Gestational diabetes [29] => }} [30] => | causes = Insulin insufficiency or gradual resistance [31] => | risks = {{Plainlist| [32] => * '''Type 1''': [[Heredity|genetics]] and environmental factors [33] => * '''Type 2''': [[Obesity]], lack of exercise, [[Heredity|genetics]],{{cite web|title=Causes of Diabetes - NIDDK|url=http://www.niddk.nih.gov/health-information/health-topics/Diabetes/causes-diabetes/Pages/index.aspx|website=National Institute of Diabetes and Digestive and Kidney Diseases|access-date=10 February 2016|date=June 2014 |url-status=live |archive-date=2 February 2016 |archive-url=https://web.archive.org/web/20160202083725/http://www.niddk.nih.gov/health-information/health-topics/Diabetes/causes-diabetes/Pages/index.aspx }} [34] => }} [35] => | diagnosis = {{Plainlist| [36] => * High [[blood sugar]] [37] => * Increased [[HbA1c]] [38] => }} [39] => | treatment = {{Plainlist| [40] => * [[Lifestyle causes of type 2 diabetes|Lifestyle changes]] [41] => * [[Diabetes medication]] [42] => }} [43] => | medication = {{Plainlist| [44] => * [[Insulin (medication)|Insulin]] [45] => * [[Anti-diabetic medication|Anti-hyperglycaemics]]{{cite web |website=MSDManuals.com |url=https://www.msdmanuals.com/professional/endocrine-and-metabolic-disorders/diabetes-mellitus-and-disorders-of-carbohydrate-metabolism/drug-treatment-of-diabetes-mellitus |title=Drug Treatment of Diabetes Mellitus |vauthors=Brutsaert EF |date=February 2017 |access-date=12 October 2018 |archive-date=12 October 2018 |archive-url=https://web.archive.org/web/20181012214514/https://www.msdmanuals.com/professional/endocrine-and-metabolic-disorders/diabetes-mellitus-and-disorders-of-carbohydrate-metabolism/drug-treatment-of-diabetes-mellitus |url-status=live }} [46] => }} [47] => | frequency = 463 million (8.8%){{cite web |title=IDF DIABETES ATLAS Ninth Edition 2019 |url=https://www.diabetesatlas.org/upload/resources/material/20200302_133351_IDFATLAS9e-final-web.pdf |website=www.diabetesatlas.org |access-date=18 May 2020 |archive-date=1 May 2020 |archive-url=https://web.archive.org/web/20200501123853/https://www.diabetesatlas.org/upload/resources/material/20200302_133351_IDFATLAS9e-final-web.pdf |url-status=live }} [48] => | deaths = 4.2 million (2019) [49] => }} [50] => [51] => '''Diabetes mellitus''', often known simply as '''diabetes''', is a group of common [[endocrine disease]]s characterized by sustained [[hyperglycemia|high blood sugar levels]].{{Cite web |title=Diabetes |url=https://www.who.int/health-topics/diabetes |url-status=live |access-date=29 January 2023 |website=[[World Health Organization]] |archive-date=29 January 2023 |archive-url=https://web.archive.org/web/20230129101252/https://www.who.int/health-topics/diabetes }}{{cite web |title=Diabetes Mellitus (DM) - Hormonal and Metabolic Disorders |url=https://www.msdmanuals.com/en-gb/home/hormonal-and-metabolic-disorders/diabetes-mellitus-dm-and-disorders-of-blood-sugar-metabolism/diabetes-mellitus-dm |website=MSD Manual Consumer Version |access-date=1 October 2022 |archive-date=1 October 2022 |archive-url=https://web.archive.org/web/20221001070047/https://www.msdmanuals.com/en-gb/home/hormonal-and-metabolic-disorders/diabetes-mellitus-dm-and-disorders-of-blood-sugar-metabolism/diabetes-mellitus-dm |url-status=live }} Diabetes is due to either the [[pancreas]] not producing enough [[insulin]], or the cells of the body becoming unresponsive to the hormone's effects.{{cite book |veditors=Shoback DG, Gardner D |title=Greenspan's basic & clinical endocrinology|year=2011|publisher=McGraw-Hill Medical|location=New York|isbn=978-0-07-162243-1|chapter=Chapter 17|edition=9th}} Classic symptoms include thirst, [[polyuria]], weight loss, and [[blurred vision]]. If left untreated, the disease can lead to various health complications, including disorders of the [[Cardiovascular disease|cardiovascular system]], [[Diabetic retinopathy|eye]], [[Diabetic nephropathy|kidney]], and [[Diabetic neuropathy|nerves]].{{cite journal |vauthors=Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN |date=July 2009 |title=Hyperglycemic crises in adult patients with diabetes |url=http://care.diabetesjournals.org/content/32/7/1335.full |url-status=live |journal=Diabetes Care |volume=32 |issue=7 |pages=1335–1343 |doi=10.2337/dc09-9032 |pmc=2699725 |pmid=19564476 |archive-url=https://web.archive.org/web/20160625075136/http://care.diabetesjournals.org/content/32/7/1335.full |archive-date=2016-06-25}} Untreated or poorly treated diabetes accounts for approximately 1.5 million deaths every year. [52] => [53] => The major types of diabetes are [[Type 1 diabetes|type 1]] and [[Type 2 diabetes|type 2]], though other forms also exist. The most common treatment for type 1 is [[insulin replacement therapy]] (insulin injections), while [[Diabetes medication|anti-diabetic medications]] (such as [[metformin]] and [[semaglutide]]) and [[Lifestyle medicine|lifestyle modifications]] can be used to manage type 2. [[Gestational diabetes]], a form that arises during [[pregnancy]] in some women, normally resolves shortly after delivery. [54] => [55] => As of 2021, an estimated 537 million people had diabetes worldwide accounting for 10.5% of the adult population, with type 2 making up about 90% of all cases. It is estimated that by 2045, approximately 783 million adults, or 1 in 8, will be living with diabetes, representing a 46% increase from the current figures.{{Cite web |title=Facts & figures |url=https://idf.org/about-diabetes/facts-figures/ |access-date=2023-08-10 |website=International Diabetes Federation |archive-date=2023-08-10 |archive-url=https://web.archive.org/web/20230810231724/https://idf.org/about-diabetes/facts-figures/ |url-status=live }} The prevalence of the disease continues to increase, most dramatically in low- and middle-income nations.{{cite journal | vauthors = De Silva AP, De Silva SH, Haniffa R, Liyanage IK, Jayasinghe S, Katulanda P, Wijeratne CN, Wijeratne S, Rajapaksa LC | display-authors = 6 | title = Inequalities in the prevalence of diabetes mellitus and its risk factors in Sri Lanka: a lower middle income country | journal = International Journal for Equity in Health | volume = 17 | issue = 1 | pages = 45 | date = April 2018 | pmid = 29665834 | pmc = 5905173 | doi = 10.1186/s12939-018-0759-3 | doi-access = free }} Rates are similar in women and men, with diabetes being the seventh leading cause of death globally.{{cite web |title=The top 10 causes of death |url=https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death |website=www.who.int |access-date=18 May 2020 |archive-date=24 September 2021 |archive-url=https://web.archive.org/web/20210924191646/https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death |url-status=live }} The global expenditure on diabetes-related healthcare is an estimated US$760 billion a year.{{cite journal | vauthors = Bommer C, Sagalova V, Heesemann E, Manne-Goehler J, Atun R, Bärnighausen T, Davies J, Vollmer S | display-authors = 6 | title = Global Economic Burden of Diabetes in Adults: Projections From 2015 to 2030 | journal = Diabetes Care | volume = 41 | issue = 5 | pages = 963–970 | date = May 2018 | pmid = 29475843 | doi = 10.2337/dc17-1962 | s2cid = 3538441 | doi-access = free }} [56] => {{TOC limit}} [57] => [58] => ==Signs and symptoms== [59] => [[File:Main symptoms of diabetes.svg|thumb|upright=1.5|Overview of the most significant symptoms of diabetes]] [[File:Diabetes complications.jpg|thumb|Retinopathy, nephropathy, and neuropathy are potential complications of diabetes]]The classic symptoms of untreated diabetes are [[polyuria]], thirst, and weight loss.{{Cite book |last1=Feather |first1=Adam |title=Kumar and Clark's Clinical Medicine |last2=Randall |first2=David |last3=Waterhouse |first3=Mona |publisher=[[Elsevier]] |year=2021 |isbn=978-0-7020-7868-2 |edition=10th |pages=699–741}} Several other non-specific signs and symptoms may also occur, including fatigue, blurred vision, and genital itchiness due to [[Candidiasis|''Candida'' infection]]. About half of affected individuals may also be asymptomatic. Type 1 presents abruptly following a pre-clinical phase, while type 2 has a more insidious onset; patients may remain asymptomatic for many years.{{Cite book |last1=Goldman |first1=Lee |title=Goldman-Cecil Medicine |last2=Schafer |first2=Andrew |publisher=[[Elsevier]] |year=2020 |isbn=978-0-323-53266-2 |edition=26th |pages=1490–1510}} [60] => [61] => [[Diabetic ketoacidosis]] is a medical emergency that occurs most commonly in type 1, but may also occur in type 2 if it has been longstanding or if the individual has significant β-cell dysfunction.{{Cite book |last1=Penman |first1=Ian |title=Davidson's Principles and Practice of Medicine |last2=Ralston |first2=Stuart |last3=Strachan |first3=Mark |last4=Hobson |first4=Richard |publisher=Elsevier |year=2023 |isbn=978-0-7020-8348-8 |edition=24th |pages=703–753}} Excessive production of [[ketone bodies]] leads to signs and symptoms including nausea, vomiting, abdominal pain, the smell of [[acetone]] in the breath, deep breathing known as [[Kussmaul breathing]], and in severe cases [[Altered level of consciousness|decreased level of consciousness]]. [[Hyperosmolar hyperglycemic state]] is another emergency characterised by dehydration secondary to severe hyperglycaemia, with resultant [[hypernatremia]] leading to an altered mental state and possibly [[coma]].{{Cite journal |last1=Willix |first1=Clare |last2=Griffiths |first2=Emma |last3=Singleton |first3=Sally |date=May 2019 |title=Hyperglycaemic presentations in type 2 diabetes |url=https://www1.racgp.org.au/ajgp/2019/may/hyperglycaemic-presentations-in-type-2-diabetes |journal=Australian Journal of General Practice |volume=48 |issue=5 |pages=263–267 |doi=10.31128/AJGP-12-18-4785 |pmid=31129935 |s2cid=167207067 |doi-access=free |access-date=2023-08-10 |archive-date=2023-08-10 |archive-url=https://web.archive.org/web/20230810230515/https://www1.racgp.org.au/ajgp/2019/may/hyperglycaemic-presentations-in-type-2-diabetes |url-status=live }} [62] => [63] => [[Hypoglycemia|Hypoglycaemia]] is a recognised complication of insulin treatment used in diabetes.{{Cite journal |last=Amiel |first=Stephanie A. |date=2021-05-01 |title=The consequences of hypoglycaemia |url=https://doi.org/10.1007/s00125-020-05366-3 |journal=Diabetologia |volume=64 |issue=5 |pages=963–970 |doi=10.1007/s00125-020-05366-3 |issn=1432-0428 |pmc=8012317 |pmid=33550443}} An acute presentation can include mild symptoms such as [[Perspiration|sweating]], trembling, and [[palpitations]], to more serious effects including [[Delirium|impaired cognition]], confusion, [[seizure]]s, [[coma]], and rarely death. Recurrent hypoglycaemic episodes may lower the glycaemic threshold at which symptoms occur, meaning mild symptoms may not appear before cognitive deterioration begins to occur. [64] => [65] => ===Long-term complications=== [66] => {{Main|Complications of diabetes}} [67] => The major long-term complications of diabetes relate to damage to [[blood vessel]]s at both [[Macrovascular disease|macrovascular]] and [[Microvascular disease|microvascular]] levels.{{Cite web |last= |first= |title=Diabetes - long-term effects |url=http://www.betterhealth.vic.gov.au/health/conditionsandtreatments/diabetes-long-term-effects |access-date=2023-08-12 |website=Better Health Channel |publisher=Department of Health |publication-place=Victoria |archive-date=2023-10-29 |archive-url=https://web.archive.org/web/20231029233716/https://www.betterhealth.vic.gov.au/health/conditionsandtreatments/diabetes-long-term-effects |url-status=live }}{{cite journal | vauthors = Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, Ingelsson E, Lawlor DA, Selvin E, Stampfer M, Stehouwer CD, Lewington S, Pennells L, Thompson A, Sattar N, White IR, Ray KK, Danesh J | display-authors = 6 | title = Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies | journal = Lancet | volume = 375 | issue = 9733 | pages = 2215–2222 | date = June 2010 | pmid = 20609967 | pmc = 2904878 | doi = 10.1016/S0140-6736(10)60484-9 }} Diabetes doubles the risk of [[cardiovascular disease]], and about 75% of deaths in people with diabetes are due to [[coronary artery disease]].{{cite journal |display-authors=6 |vauthors=O'Gara PT, Kushner FG, Ascheim DD, Casey DE, Chung MK, de Lemos JA, Ettinger SM, Fang JC, Fesmire FM, Franklin BA, Granger CB, Krumholz HM, Linderbaum JA, Morrow DA, Newby LK, Ornato JP, Ou N, Radford MJ, Tamis-Holland JE, Tommaso CL, Tracy CM, Woo YJ, Zhao DX, Anderson JL, Jacobs AK, Halperin JL, Albert NM, Brindis RG, Creager MA, DeMets D, Guyton RA, Hochman JS, Kovacs RJ, Kushner FG, Ohman EM, Stevenson WG, Yancy CW |date=January 2013 |title=2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines |journal=Circulation |volume=127 |issue=4 |pages=e368 |doi=10.1161/CIR.0b013e3182742cf6 |pmid=23247304 |doi-access=free}} Other macrovascular morbidities include [[stroke]] and [[peripheral artery disease]].{{cite journal |vauthors=Papatheodorou K, Banach M, Bekiari E, Rizzo M, Edmonds M |date=11 March 2018 |title=Complications of Diabetes 2017 |journal=Journal of Diabetes Research |volume=2018 |pages=3086167 |doi=10.1155/2018/3086167 |pmc=5866895 |pmid=29713648 |doi-access=free}} [68] => [69] => Microvascular disease affects the [[eye]]s, [[kidney]]s, and [[nerve]]s. Damage to the retina, known as [[diabetic retinopathy]], is the most common cause of blindness in people of working age. The eyes can also be affected in other ways, including development of [[cataract]] and [[glaucoma]]. It is recommended that people with diabetes visit an [[optometrist]] or [[ophthalmologist]] once a year.{{Cite web |title=Diabetes eye care |url=https://medlineplus.gov/ency/patientinstructions/000078.htm |access-date=2018-03-27 |website=MedlinePlus |publisher=National Library of Medicine |publication-place=Maryland |archive-date=2018-03-28 |archive-url=https://web.archive.org/web/20180328102348/https://medlineplus.gov/ency/patientinstructions/000078.htm |url-status=live }} [70] => [71] => [[Diabetic nephropathy]] is a major cause of [[chronic kidney disease]], accounting for over 50% of patients on [[Kidney dialysis|dialysis]] in the United States.{{Cite book |last1=Wing |first1=Edward J |title=Cecil Essentials of Medicine |last2=Schiffman |first2=Fred |publisher=[[Elsevier]] |year=2022 |isbn=978-0-323-72271-1 |edition=10th |location=Pennsylvania |pages=282–297, 662–677}} [[Diabetic neuropathy]], damage to nerves, manifests in various ways, including [[sensory loss]], [[neuropathic pain]], and [[autonomic dysfunction]] (such as [[Orthostatic hypotension|postural hypotension]], [[Diarrhea|diarrhoea]], and [[erectile dysfunction]]). Loss of pain sensation predisposes to trauma that can lead to [[Diabetic foot|diabetic foot problems]] (such as [[ulcer]]ation), the most common cause of non-traumatic lower-limb [[amputation]]. [72] => [73] => Based on extensive data and numerous cases of gallstone disease, it appears that a causal link might exist between type 2 diabetes and gallstones. People with diabetes are at a higher risk of developing gallstones compared to those without diabetes.{{Cite journal |last1=Yuan |first1=Shuai |last2=Gill |first2=Dipender |last3=Giovannucci |first3=Edward L. |last4=Larsson |first4=Susanna C. |date=March 2022 |title=Obesity, Type 2 Diabetes, Lifestyle Factors, and Risk of Gallstone Disease: A Mendelian Randomization Investigation |journal=Clinical Gastroenterology and Hepatology |volume=20 |issue=3 |pages=e529–e537 |doi=10.1016/j.cgh.2020.12.034|pmid=33418132 |doi-access=free |hdl=10044/1/86461 |hdl-access=free }} [74] => [75] => There is a link between [[cognitive deficit]] and diabetes; studies have shown that diabetic individuals are at a greater risk of cognitive decline, and have a greater rate of decline compared to those without the disease.{{cite journal |vauthors=Cukierman T, Gerstein HC, Williamson JD |date=December 2005 |title=Cognitive decline and dementia in diabetes--systematic overview of prospective observational studies |journal=Diabetologia |volume=48 |issue=12 |pages=2460–2469 |doi=10.1007/s00125-005-0023-4 |pmid=16283246 |doi-access=free}} The condition also predisposes to [[Falls in older adults|falls in the elderly]], especially those treated with [[insulin]].{{cite journal |vauthors=Yang Y, Hu X, Zhang Q, Zou R |date=November 2016 |title=Diabetes mellitus and risk of falls in older adults: a systematic review and meta-analysis |journal=Age and Ageing |volume=45 |issue=6 |pages=761–767 |doi=10.1093/ageing/afw140 |pmid=27515679 |doi-access=free}} [76] => [77] => ==Causes== [78] => {| class="wikitable" style="float:right; margin:10px" [79] => |+Comparison of type 1 and 2 diabetes{{cite book |title=Williams textbook of endocrinology |publisher=Elsevier/Saunders |isbn=978-1-4377-0324-5 |pages=1371–1435 |edition=12th|year=2011 }} [80] => |- [81] => ! Feature !! Type 1 diabetes !! Type 2 diabetes [82] => |- [83] => ! Onset [84] => | Sudden||Gradual [85] => |- [86] => ! Age at onset [87] => | Any age; average age at diagnosis being 24.https://www.usnews.com/news/health-news/articles/2023-09-28/over-a-third-of-adults-with-type-1-diabetes-werent-diagnosed-until-after-30 || Mostly in adults [88] => |- [89] => ! Body size [90] => | Thin or normal{{cite journal |vauthors=Lambert P, Bingley PJ | title = What is Type 1 Diabetes? | journal = Medicine | volume = 30 | pages = 1–5 | year = 2002 | doi = 10.1383/medc.30.1.1.28264 }} || Often [[obese]] [91] => |- [92] => ! [[diabetic ketoacidosis|Ketoacidosis]] [93] => | Common || Rare [94] => |- [95] => ! [[Autoantibodies]] [96] => | Usually present || Absent [97] => |- [98] => ! Endogenous insulin [99] => | Low or absent || Normal, decreased
or increased [100] => |- [101] => ! Heritability [102] => | 0.69 to 0.88{{cite journal | vauthors = Skov J, Eriksson D, Kuja-Halkola R, Höijer J, Gudbjörnsdottir S, Svensson AM, Magnusson PK, Ludvigsson JF, Kämpe O, Bensing S | display-authors = 6 | title = Co-aggregation and heritability of organ-specific autoimmunity: a population-based twin study | journal = European Journal of Endocrinology | volume = 182 | issue = 5 | pages = 473–480 | date = May 2020 | pmid = 32229696 | doi = 10.1530/EJE-20-0049 | pmc = 7182094 }}{{cite journal | vauthors = Hyttinen V, Kaprio J, Kinnunen L, Koskenvuo M, Tuomilehto J | title = Genetic liability of type 1 diabetes and the onset age among 22,650 young Finnish twin pairs: a nationwide follow-up study | journal = Diabetes | volume = 52 | issue = 4 | pages = 1052–1055 | date = April 2003 | pmid = 12663480 | doi = 10.2337/diabetes.52.4.1052 | doi-access = free }}{{cite journal | vauthors = Condon J, Shaw JE, Luciano M, Kyvik KO, Martin NG, Duffy DL | title = A study of diabetes mellitus within a large sample of Australian twins | journal = Twin Research and Human Genetics | volume = 11 | issue = 1 | pages = 28–40 | date = February 2008 | pmid = 18251672 | doi = 10.1375/twin.11.1.28 | s2cid = 18072879 | url = https://www.pure.ed.ac.uk/ws/files/11913813/study_of_diabetes_mellitus_within_a_large_sample_of_Australian_twins.pdf | access-date = 2021-12-27 | archive-date = 2023-07-01 | archive-url = https://web.archive.org/web/20230701154034/https://www.pure.ed.ac.uk/ws/files/11913813/study_of_diabetes_mellitus_within_a_large_sample_of_Australian_twins.pdf | url-status = live }}|| 0.47 to 0.77{{cite journal | vauthors = Willemsen G, Ward KJ, Bell CG, Christensen K, Bowden J, Dalgård C, Harris JR, Kaprio J, Lyle R, Magnusson PK, Mather KA, Ordoňana JR, Perez-Riquelme F, Pedersen NL, Pietiläinen KH, Sachdev PS, Boomsma DI, Spector T | display-authors = 6 | title = The Concordance and Heritability of Type 2 Diabetes in 34,166 Twin Pairs From International Twin Registers: The Discordant Twin (DISCOTWIN) Consortium | journal = Twin Research and Human Genetics | volume = 18 | issue = 6 | pages = 762–771 | date = December 2015 | pmid = 26678054 | doi = 10.1017/thg.2015.83 | s2cid = 17854531 | doi-access = free }} [103] => |- [104] => ! Prevalence [105] => (age standardized) [106] => | <2 per 1,000{{cite journal | vauthors = Lin X, Xu Y, Pan X, Xu J, Ding Y, Sun X, Song X, Ren Y, Shan PF | display-authors = 6 | title = Global, regional, and national burden and trend of diabetes in 195 countries and territories: an analysis from 1990 to 2025 | journal = Scientific Reports | volume = 10 | issue = 1 | pages = 14790 | date = September 2020 | pmid = 32901098 | doi = 10.1038/s41598-020-71908-9 | pmc = 7478957 | bibcode = 2020NatSR..1014790L }}|| ~6% (men), ~5% (women){{cite journal | vauthors = Tinajero MG, Malik VS | title = An Update on the Epidemiology of Type 2 Diabetes: A Global Perspective | journal = Endocrinology and Metabolism Clinics of North America | volume = 50 | issue = 3 | pages = 337–355 | date = September 2021 | pmid = 34399949 | doi = 10.1016/j.ecl.2021.05.013 }} [107] => |} [108] => [109] => Diabetes is classified by the [[World Health Organization]] into six categories: [[type 1 diabetes]], [[type 2 diabetes]], hybrid forms of diabetes (including [[Latent autoimmune diabetes of adults|slowly evolving, immune-mediated diabetes of adults]] and [[Ketosis-prone diabetes|ketosis-prone type 2 diabetes]]), hyperglycemia first detected during pregnancy, "other specific types", and "unclassified diabetes".{{Cite report |url=https://apps.who.int/iris/rest/bitstreams/1233344/retrieve |title=Classification of diabetes mellitus 2019 |date=2019 |publisher=World Health Organisation |location=Geneva |isbn=978-92-4-151570-2 |access-date=2023-08-15 |archive-date=2023-03-06 |archive-url=https://web.archive.org/web/20230306070305/https://apps.who.int/iris/rest/bitstreams/1233344/retrieve |url-status=live }} Diabetes is a more variable disease than once thought, and individuals may have a combination of forms.{{cite journal |vauthors=Tuomi T, Santoro N, Caprio S, Cai M, Weng J, Groop L |date=March 2014 |title=The many faces of diabetes: a disease with increasing heterogeneity |journal=Lancet |volume=383 |issue=9922 |pages=1084–1094 |doi=10.1016/S0140-6736(13)62219-9 |pmid=24315621 |s2cid=12679248}} [110] => [111] => ===Type 1=== [112] => {{Main|Type 1 diabetes}} [113] => Type 1 accounts for 5 to 10% of diabetes cases and is the most common type diagnosed in patients under 20 years;{{Cite book |last1=Kumar |first1=V |title=Robbins & Cotran Pathologic Basis of Disease |last2=Abbas |first2=A |last3=Aster |first3=J |publisher=[[Elsevier]] |year=2021 |isbn=978-0-323-60992-0 |edition=10th |location=Pennsylvania |pages=1065–1132}} however, the older term "juvenile-onset diabetes" is no longer used as the disease not uncommonly has onset in adulthood. The disease is characterized by loss of the insulin-producing [[beta cell]]s of the [[pancreatic islets]], leading to severe insulin deficiency, and can be further classified as [[immune-mediated]] or [[Idiopathic disease|idiopathic]] (without known cause). The majority of cases are immune-mediated, in which a [[T cell]]-mediated [[autoimmunity|autoimmune]] attack causes loss of beta cells and thus insulin deficiency.{{cite journal | vauthors = Rother KI | title = Diabetes treatment--bridging the divide | journal = The New England Journal of Medicine | volume = 356 | issue = 15 | pages = 1499–1501 | date = April 2007 | pmid = 17429082 | pmc = 4152979 | doi = 10.1056/NEJMp078030 }} Patients often have irregular and unpredictable blood sugar levels due to very low insulin and an impaired counter-response to hypoglycaemia.{{cite web |last=Brutsaert |first=EF |date=September 2022 |title=Diabetes Mellitus (DM) |url=https://www.msdmanuals.com/professional/endocrine-and-metabolic-disorders/diabetes-mellitus-and-disorders-of-carbohydrate-metabolism/diabetes-mellitus-dm |access-date=2023-08-15 |website=MSD Manual Professional Version |publisher=[[Merck & Co.|Merck Publishing]] |archive-date=2023-08-15 |archive-url=https://web.archive.org/web/20230815124233/https://www.msdmanuals.com/professional/endocrine-and-metabolic-disorders/diabetes-mellitus-and-disorders-of-carbohydrate-metabolism/diabetes-mellitus-dm |url-status=live }} [[File:Type 1 Diabetes Mellitus.jpg|thumb|Autoimmune attack in type 1 diabetes.]] [114] => Type 1 diabetes is partly [[Genetic disorder|inherited]], with multiple genes, including certain [[Human leukocyte antigen|HLA genotypes]], known to influence the risk of diabetes. In genetically susceptible people, the onset of diabetes can be triggered by one or more [[environmental factor]]s,{{cite journal | vauthors = Petzold A, Solimena M, Knoch KP | title = Mechanisms of Beta Cell Dysfunction Associated With Viral Infection | journal = Current Diabetes Reports | volume = 15 | issue = 10 | pages = 73 | date = October 2015 | pmid = 26280364 | pmc = 4539350 | doi = 10.1007/s11892-015-0654-x | type = Review | quote = So far, none of the hypotheses accounting for virus-induced beta cell autoimmunity has been supported by stringent evidence in humans, and the involvement of several mechanisms rather than just one is also plausible. }} such as a [[viral infection]] or diet. Several viruses have been implicated, but to date there is no stringent evidence to support this hypothesis in humans.{{cite journal | vauthors = Butalia S, Kaplan GG, Khokhar B, Rabi DM | title = Environmental Risk Factors and Type 1 Diabetes: Past, Present, and Future | journal = Canadian Journal of Diabetes | volume = 40 | issue = 6 | pages = 586–593 | date = December 2016 | pmid = 27545597 | doi = 10.1016/j.jcjd.2016.05.002 | type = Review }} [115] => [116] => Type 1 diabetes can occur at any age, and a significant proportion is diagnosed during adulthood. [[Latent autoimmune diabetes of adults]] (LADA) is the diagnostic term applied when type 1 diabetes develops in adults; it has a slower onset than the same condition in children. Given this difference, some use the unofficial term "type 1.5 diabetes" for this condition. Adults with LADA are frequently initially misdiagnosed as having type 2 diabetes, based on age rather than a cause.{{cite journal | vauthors = Laugesen E, Østergaard JA, Leslie RD | title = Latent autoimmune diabetes of the adult: current knowledge and uncertainty | journal = Diabetic Medicine | volume = 32 | issue = 7 | pages = 843–852 | date = July 2015 | pmid = 25601320 | pmc = 4676295 | doi = 10.1111/dme.12700 }} LADA leaves adults with higher levels of insulin production than type 1 diabetes, but not enough insulin production for healthy blood sugar levels.{{Cite web |title=What Is Diabetes? |url=https://www.diabetesdaily.com/learn-about-diabetes/basics/what-is-diabetes/ |access-date=2023-09-10 |website=Diabetes Daily |archive-date=2023-10-04 |archive-url=https://web.archive.org/web/20231004071449/https://www.diabetesdaily.com/learn-about-diabetes/basics/what-is-diabetes/ |url-status=live }}{{Cite journal |last1=Nolasco-Rosales |first1=Germán Alberto |last2=Ramírez-González |first2=Dania |last3=Rodríguez-Sánchez |first3=Ester |last4=Ávila-Fernandez |first4=Ángela |last5=Villar-Juarez |first5=Guillermo Efrén |last6=González-Castro |first6=Thelma Beatriz |last7=Tovilla-Zárate |first7=Carlos Alfonso |last8=Guzmán-Priego |first8=Crystell Guadalupe |last9=Genis-Mendoza |first9=Alma Delia |last10=Ble-Castillo |first10=Jorge Luis |last11=Marín-Medina |first11=Alejandro |last12=Juárez-Rojop |first12=Isela Esther |date=2023-04-29 |title=Identification and phenotypic characterization of patients with LADA in a population of southeast Mexico |journal=Scientific Reports |volume=13 |issue=1 |pages=7029 |doi=10.1038/s41598-023-34171-2 |issn=2045-2322 |pmid=37120620|pmc=10148806 |bibcode=2023NatSR..13.7029N }} [117] => [118] => ===Type 2=== [119] => {{Main|Type 2 diabetes}} [120] => [[File:Type 2 Diabetes Mellitus.jpg|thumb|Reduced insulin secretion or weaker effect of insulin on its receptor leads to high glucose content in the blood.]] [121] => Type 2 diabetes is characterized by [[insulin resistance]], which may be combined with relatively reduced insulin secretion. The defective responsiveness of body tissues to insulin is believed to involve the [[insulin receptor]].{{Citation |last=Freeman |first=Andrew M. |title=Insulin Resistance |date=2024 |work=StatPearls |url=http://www.ncbi.nlm.nih.gov/books/NBK507839/ |access-date=2024-02-13 |place=Treasure Island (FL) |publisher=StatPearls Publishing |pmid=29939616 |last2=Acevedo |first2=Luis A. |last3=Pennings |first3=Nicholas |archive-date=2024-02-07 |archive-url=https://web.archive.org/web/20240207020904/https://www.ncbi.nlm.nih.gov/books/NBK507839/ |url-status=live }} However, the specific defects are not known. Diabetes mellitus cases due to a known defect are classified separately. Type 2 diabetes is the most common type of diabetes mellitus accounting for 95% of diabetes. Many people with type 2 diabetes have evidence of [[prediabetes]] (impaired fasting glucose and/or impaired glucose tolerance) before meeting the criteria for type 2 diabetes.{{cite journal | author = American Diabetes Association | title = 2. Classification and Diagnosis of Diabetes | journal = Diabetes Care | volume = 40 | issue = Suppl 1 | pages = S11–S24 | date = January 2017 | pmid = 27979889 | doi = 10.2337/dc17-S005 | doi-access = free }} The progression of prediabetes to overt type 2 diabetes can be slowed or reversed by lifestyle changes or [[Anti-diabetic drug|medications]] that improve insulin sensitivity or reduce the [[Glycogenolysis|liver's glucose production]].{{cite journal | vauthors = Carris NW, Magness RR, Labovitz AJ | title = Prevention of Diabetes Mellitus in Patients With Prediabetes | journal = The American Journal of Cardiology | volume = 123 | issue = 3 | pages = 507–512 | date = February 2019 | pmid = 30528418 | pmc = 6350898 | doi = 10.1016/j.amjcard.2018.10.032 }} [122] => [123] => Type 2 diabetes is primarily due to lifestyle factors and genetics.{{cite journal | vauthors = Risérus U, Willett WC, Hu FB | title = Dietary fats and prevention of type 2 diabetes | journal = Progress in Lipid Research | volume = 48 | issue = 1 | pages = 44–51 | date = January 2009 | pmid = 19032965 | pmc = 2654180 | doi = 10.1016/j.plipres.2008.10.002 }} A number of lifestyle factors are known to be important to the development of type 2 diabetes, including [[obesity]] (defined by a [[body mass index]] of greater than 30), lack of [[physical activity]], poor [[Diet (nutrition)|diet]], [[stress (biology)|stress]], and [[urbanization]].{{Cite journal |last1=Fletcher |first1=Barbara |last2=Gulanick |first2=Meg |last3=Lamendola |first3=Cindy |date=January 2002 |title=Risk factors for type 2 diabetes mellitus |url=https://pubmed.ncbi.nlm.nih.gov/11800065 |journal=The Journal of Cardiovascular Nursing |volume=16 |issue=2 |pages=17–23 |doi=10.1097/00005082-200201000-00003 |issn=0889-4655 |pmid=11800065 |access-date=2023-10-12 |archive-date=2023-10-20 |archive-url=https://web.archive.org/web/20231020123710/https://pubmed.ncbi.nlm.nih.gov/11800065/ |url-status=live }} Excess body fat is associated with 30% of cases in people of Chinese and Japanese descent, 60–80% of cases in those of European and African descent, and 100% of Pima Indians and Pacific Islanders. Even those who are not obese may have a high [[waist–hip ratio]]. [124] => [125] => Dietary factors such as [[sugar]]-sweetened drinks are associated with an increased risk.{{cite journal | vauthors = Malik VS, Popkin BM, Bray GA, Després JP, Hu FB | title = Sugar-sweetened beverages, obesity, type 2 diabetes mellitus, and cardiovascular disease risk | journal = Circulation | volume = 121 | issue = 11 | pages = 1356–1364 | date = March 2010 | pmid = 20308626 | pmc = 2862465 | doi = 10.1161/CIRCULATIONAHA.109.876185 }}{{cite journal | vauthors = Malik VS, Popkin BM, Bray GA, Després JP, Willett WC, Hu FB | title = Sugar-sweetened beverages and risk of metabolic syndrome and type 2 diabetes: a meta-analysis | journal = Diabetes Care | volume = 33 | issue = 11 | pages = 2477–2483 | date = November 2010 | pmid = 20693348 | pmc = 2963518 | doi = 10.2337/dc10-1079 }} The type of [[fat]]s in the diet is also important, with [[saturated fat]] and [[trans fat]]s increasing the risk and [[polyunsaturated fat|polyunsaturated]] and [[monounsaturated fat]] decreasing the risk. Eating [[white rice]] excessively may increase the risk of diabetes, especially in Chinese and Japanese people.{{cite journal | vauthors = Hu EA, Pan A, Malik V, Sun Q | title = White rice consumption and risk of type 2 diabetes: meta-analysis and systematic review | journal = BMJ | volume = 344 | pages = e1454 | date = March 2012 | pmid = 22422870 | pmc = 3307808 | doi = 10.1136/bmj.e1454 }} Lack of physical activity may increase the risk of diabetes in some people.{{cite journal | vauthors = Lee IM, Shiroma EJ, Lobelo F, Puska P, Blair SN, Katzmarzyk PT | title = Effect of physical inactivity on major non-communicable diseases worldwide: an analysis of burden of disease and life expectancy | journal = Lancet | volume = 380 | issue = 9838 | pages = 219–229 | date = July 2012 | pmid = 22818936 | pmc = 3645500 | doi = 10.1016/S0140-6736(12)61031-9 }} [126] => [127] => [[Adverse Childhood Experiences Study|Adverse childhood experiences]], including abuse, neglect, and household difficulties, increase the likelihood of type 2 diabetes later in life by 32%, with [[neglect]] having the strongest effect.{{cite journal | vauthors = Huang H, Yan P, Shan Z, Chen S, Li M, Luo C, Gao H, Hao L, Liu L | display-authors = 6 | title = Adverse childhood experiences and risk of type 2 diabetes: A systematic review and meta-analysis | journal = Metabolism | volume = 64 | issue = 11 | pages = 1408–1418 | date = November 2015 | pmid = 26404480 | doi = 10.1016/j.metabol.2015.08.019 }} [128] => [129] => [[Antipsychotic|Antipsychotic medication]] side effects (specifically metabolic abnormalities, [[dyslipidemia]] and weight gain) and unhealthy lifestyles (including poor diet and decreased [[physical activity]]), are potential risk factors.{{cite journal | vauthors = Zhang Y, Liu Y, Su Y, You Y, Ma Y, Yang G, Song Y, Liu X, Wang M, Zhang L, Kou C | display-authors = 6 | title = The metabolic side effects of 12 antipsychotic drugs used for the treatment of schizophrenia on glucose: a network meta-analysis | journal = BMC Psychiatry | volume = 17 | issue = 1 | pages = 373 | date = November 2017 | pmid = 29162032 | pmc = 5698995 | doi = 10.1186/s12888-017-1539-0 | doi-access = free }} [130] => [131] => ===Gestational diabetes=== [132] => {{Main|Gestational diabetes}} [133] => Gestational diabetes resembles type 2 diabetes in several respects, involving a combination of relatively inadequate insulin secretion and responsiveness. It occurs in about 2–10% of all [[pregnancy|pregnancies]] and may improve or disappear after delivery.{{cite web|title=National Diabetes Clearinghouse (NDIC): National Diabetes Statistics 2011|url=http://diabetes.niddk.nih.gov/dm/pubs/statistics/#Gestational|publisher=U.S. Department of Health and Human Services|access-date=22 April 2014|url-status=dead|archive-url=https://web.archive.org/web/20140417143052/http://diabetes.niddk.nih.gov/dm/pubs/statistics/#Gestational|archive-date=17 April 2014}} It is recommended that all pregnant women get tested starting around 24–28 weeks gestation.{{Cite journal| vauthors = Soldavini J |date=November 2019|title=Krause's Food & The Nutrition Care Process|journal=Journal of Nutrition Education and Behavior|volume=51|issue=10|pages=1225|doi=10.1016/j.jneb.2019.06.022|s2cid=209272489|issn=1499-4046}} It is most often diagnosed in the second or third trimester because of the increase in insulin-antagonist hormone levels that occurs at this time. However, after pregnancy approximately 5–10% of women with gestational diabetes are found to have another form of diabetes, most commonly type 2. Gestational diabetes is fully treatable, but requires careful medical supervision throughout the pregnancy. Management may include dietary changes, blood glucose monitoring, and in some cases, insulin may be required.{{Cite web|url=https://www.niddk.nih.gov/health-information/diabetes/overview/what-is-diabetes/gestational/management-treatment|title=Managing & Treating Gestational Diabetes {{!}} NIDDK|website=National Institute of Diabetes and Digestive and Kidney Diseases|access-date=2019-05-06|archive-date=2019-05-06|archive-url=https://web.archive.org/web/20190506202142/https://www.niddk.nih.gov/health-information/diabetes/overview/what-is-diabetes/gestational/management-treatment|url-status=live}} [134] => [135] => Though it may be transient, untreated gestational diabetes can damage the health of the fetus or mother. Risks to the baby include [[macrosomia]] (high birth weight), [[Congenital heart defect|congenital heart]] and [[central nervous system]] abnormalities, and [[skeletal muscle]] malformations. Increased levels of insulin in a fetus's blood may inhibit fetal [[surfactant]] production and cause [[infant respiratory distress syndrome]]. A [[Bilirubin#Hyperbilirubinemia|high blood bilirubin level]] may result from [[hemolysis|red blood cell destruction]]. In severe cases, perinatal death may occur, most commonly as a result of poor placental perfusion due to vascular impairment. [[Labor induction]] may be indicated with decreased placental function. A [[caesarean section]] may be performed if there is marked [[fetal distress]]{{cite journal | vauthors = Tarvonen M, Hovi P, Sainio S, Vuorela P, Andersson S, Teramo K | title = Intrapartal cardiotocographic patterns and hypoxia-related perinatal outcomes in pregnancies complicated by gestational diabetes mellitus | journal = Acta Diabetologica | volume = 58 | issue = 11 | pages = 1563–1573 | date = November 2021 | pmid = 34151398 | pmc = 8505288 | doi = 10.1007/s00592-021-01756-0 | s2cid = 235487220 | doi-access = free }} or an increased risk of injury associated with macrosomia, such as [[shoulder dystocia]].{{Cite book |author=National Collaborating Centre for Women's and Children's Health |date=February 2015 |chapter=Intrapartum care |chapter-url=https://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0080685/ |title=Diabetes in Pregnancy: Management of diabetes and its complications from preconception to the postnatal period |publisher=National Institute for Health and Care Excellence (UK) |access-date=2018-08-21 |archive-date=2021-08-28 |archive-url=https://web.archive.org/web/20210828061326/https://www.ncbi.nlm.nih.gov/books/NBK328350/ |url-status=live }} [136] => [137] => ===Other types=== [138] => [[Maturity onset diabetes of the young]] (MODY) is a rare [[Dominance (genetics)|autosomal dominant]] inherited form of diabetes, due to one of several single-gene mutations causing defects in insulin production.{{cite web|title=Monogenic Forms of Diabetes|url=https://www.niddk.nih.gov/health-information/diabetes/overview/what-is-diabetes/monogenic-neonatal-mellitus-mody#3|website=National institute of diabetes and digestive and kidney diseases|publisher=US NIH|access-date=12 March 2017|url-status=live|archive-url=https://web.archive.org/web/20170312195627/https://www.niddk.nih.gov/health-information/diabetes/overview/what-is-diabetes/monogenic-neonatal-mellitus-mody#3|archive-date=12 March 2017}} It is significantly less common than the three main types, constituting 1–2% of all cases. The name of this disease refers to early hypotheses as to its nature. Being due to a defective gene, this disease varies in age at presentation and in severity according to the specific gene defect; thus, there are at least 13 subtypes of MODY. People with MODY often can control it without using insulin.{{cite journal | vauthors = Thanabalasingham G, Owen KR | title = Diagnosis and management of maturity onset diabetes of the young (MODY) | journal = BMJ | volume = 343 | issue = oct19 3 | pages = d6044 | date = October 2011 | pmid = 22012810 | doi = 10.1136/bmj.d6044 | s2cid = 44891167 }} [139] => [140] => Some cases of diabetes are caused by the body's tissue receptors not responding to insulin (even when insulin levels are normal, which is what separates it from type 2 diabetes); this form is very uncommon. Genetic mutations ([[Dominance (genetics)|autosomal]] or [[Mitochondrion|mitochondrial]]) can lead to defects in beta cell function. Abnormal insulin action may also have been genetically determined in some cases. Any disease that causes extensive damage to the pancreas may lead to diabetes (for example, [[chronic pancreatitis]] and [[cystic fibrosis]]). Diseases associated with excessive secretion of [[insulin receptor|insulin-antagonistic]] [[hormone]]s can cause diabetes (which is typically resolved once the hormone excess is removed). Many drugs impair insulin secretion and some toxins damage pancreatic beta cells, whereas others increase [[insulin resistance]] (especially [[glucocorticoid]]s which can provoke "[[steroid diabetes]]"). The [[ICD-10]] (1992) diagnostic entity, ''malnutrition-related diabetes mellitus'' (ICD-10 code E12), was deprecated by the [[World Health Organization]] (WHO) when the current taxonomy was introduced in 1999.{{cite web |publisher=[[World Health Organization]] |title=Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications |year=1999 |url=http://whqlibdoc.who.int/hq/1999/WHO_NCD_NCS_99.2.pdf |url-status=live |archive-url=https://web.archive.org/web/20030308005119/http://whqlibdoc.who.int/hq/1999/WHO_NCD_NCS_99.2.pdf |archive-date=2003-03-08}} [141] => Yet another form of diabetes that people may develop is [[double diabetes]]. This is when a type 1 diabetic becomes insulin resistant, the hallmark for type 2 diabetes or has a family history for type 2 diabetes.{{cite journal | vauthors = Cleland SJ, Fisher BM, Colhoun HM, Sattar N, Petrie JR | title = Insulin resistance in type 1 diabetes: what is 'double diabetes' and what are the risks? | journal = Diabetologia | volume = 56 | issue = 7 | pages = 1462–1470 | date = July 2013 | pmid = 23613085 | pmc = 3671104 | doi = 10.1007/s00125-013-2904-2 | publisher = National Library of Medicine }} It was first discovered in 1990 or 1991. [142] => [143] => The following is a list of disorders that may increase the risk of diabetes:Unless otherwise specified, reference is: Table 20-5 in {{Cite book|author1=Mitchell, Richard Sheppard |author2=Kumar, Vinay |author3=Abbas, Abul K. |author4=Fausto, Nelson |title=Robbins Basic Pathology|publisher=Saunders |location=Philadelphia |isbn=978-1-4160-2973-1 |edition=8th |year=2007 }} [144] => {{Col-float-begin}} [145] => * Genetic defects of β-cell function [146] => ** [[Maturity onset diabetes of the young]] [147] => ** Mitochondrial DNA mutations [148] => * Genetic defects in insulin processing or insulin action [149] => ** Defects in [[proinsulin]] conversion [150] => ** Insulin gene mutations [151] => ** Insulin receptor mutations [152] => * Exocrine pancreatic defects (see [[Type 3c diabetes]], i.e. pancreatogenic diabetes) [153] => ** [[Chronic pancreatitis]] [154] => ** [[Pancreatectomy]] [155] => ** [[Pancreatic neoplasia]] [156] => ** [[Cystic fibrosis]] [157] => ** [[Hemochromatosis]] [158] => ** [[Fibrocalculous pancreatopathy]] [159] => {{Col-float-break}} [160] => * [[Endocrinopathies]] [161] => ** Growth hormone excess ([[acromegaly]]) [162] => ** [[Cushing syndrome]] [163] => ** [[Hyperthyroidism]] [164] => ** [[Hypothyroidism]] [165] => ** [[Pheochromocytoma]] [166] => ** [[Glucagonoma]] [167] => * Infections [168] => ** [[Cytomegalovirus infection]] [169] => ** [[Coxsackie B4 virus|Coxsackievirus B]] [170] => * Drugs [171] => ** [[Glucocorticoids]] [172] => ** [[Thyroid hormone]] [173] => ** [[β-adrenergic agonist]]s [174] => ** [[Statins]]{{cite journal | vauthors = Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, Seshasai SR, McMurray JJ, Freeman DJ, Jukema JW, Macfarlane PW, Packard CJ, Stott DJ, Westendorp RG, Shepherd J, Davis BR, Pressel SL, Marchioli R, Marfisi RM, Maggioni AP, Tavazzi L, Tognoni G, Kjekshus J, Pedersen TR, Cook TJ, Gotto AM, Clearfield MB, Downs JR, Nakamura H, Ohashi Y, Mizuno K, Ray KK, Ford I | display-authors = 6 | title = Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials | journal = Lancet | volume = 375 | issue = 9716 | pages = 735–742 | date = February 2010 | pmid = 20167359 | doi = 10.1016/S0140-6736(09)61965-6 | s2cid = 11544414 }} [175] => {{Col-float-end}} [176] => [177] => ==Pathophysiology== [178] => [[File:Suckale08 fig3 glucose insulin day.png|thumb|upright=1.4|The fluctuation of [[Blood sugar level|blood sugar]] (red) and the sugar-lowering hormone [[insulin]] (blue) in humans during the course of a day with three meals. One of the effects of a [[sucrose|sugar]]-rich vs a [[starch]]-rich meal is highlighted.]] [179] => [[File:Glucose-insulin-release.svg|thumb|upright=1.4|Mechanism of insulin release in normal pancreatic [[beta cell]]s. Insulin production is more or less constant within the beta cells. Its release is triggered by food, chiefly food containing absorbable glucose.]] [180] => [[Insulin]] is the principal hormone that regulates the uptake of [[glucose]] from the blood into most cells of the body, especially liver, adipose tissue and muscle, except smooth muscle, in which insulin acts via the [[IGF-1]].{{citation needed|date=June 2021}} Therefore, deficiency of insulin or the insensitivity of its [[Receptor (biochemistry)|receptors]] play a central role in all forms of diabetes mellitus.{{cite web |title=Insulin Basics |url=https://diabetes.org/healthy-living/medication-treatments/insulin-other-injectables/insulin-basics |publisher=American Diabetes Association |access-date=25 June 2023 |url-status=live |archive-url=https://web.archive.org/web/20230621163852/https://diabetes.org/healthy-living/medication-treatments/insulin-other-injectables/insulin-basics |archive-date=21 June 2023}} [181] => [182] => The body obtains glucose from three main sources: the intestinal absorption of food; the breakdown of [[glycogen]] ([[glycogenolysis]]), the storage form of glucose found in the liver; and [[gluconeogenesis]], the generation of glucose from non-carbohydrate substrates in the body.{{cite book |veditors=Shoback DG, Gardner D |title=Greenspan's basic & clinical endocrinology |year=2011 |publisher=McGraw-Hill Medical |isbn=978-0-07-162243-1|edition=9th}} Insulin plays a critical role in regulating glucose levels in the body. Insulin can inhibit the breakdown of glycogen or the process of gluconeogenesis, it can stimulate the transport of glucose into fat and muscle cells, and it can stimulate the storage of glucose in the form of glycogen. [183] => [184] => Insulin is released into the blood by beta cells (β-cells), found in the [[islets of Langerhans]] in the pancreas, in response to rising levels of blood glucose, typically after eating. Insulin is used by about two-thirds of the body's cells to absorb glucose from the blood for use as fuel, for conversion to other needed molecules, or for storage. Lower glucose levels result in decreased insulin release from the beta cells and in the breakdown of glycogen to glucose. This process is mainly controlled by the hormone [[glucagon]], which acts in the opposite manner to insulin.{{cite book|vauthors=Barrett KE, etal |title=Ganong's review of medical physiology|year=2012 |publisher=McGraw-Hill Medical |isbn=978-0-07-178003-2 |edition=24th}} [185] => [186] => If the amount of insulin available is insufficient, or if cells respond poorly to the effects of insulin ([[insulin resistance]]), or if the insulin itself is defective, then glucose is not absorbed properly by the body cells that require it, and is not stored appropriately in the liver and muscles. The net effect is persistently high levels of blood glucose, poor [[Protein biosynthesis|protein synthesis]], and other metabolic derangements, such as metabolic [[acidosis]] in cases of complete insulin deficiency. [187] => [188] => When there is too much glucose in the blood for a long time, the [[kidneys]] cannot absorb it all (reach a threshold of [[reabsorption]]) and the extra glucose gets passed out of the body through [[urine]] ([[glycosuria]]).{{cite book |vauthors=Murray RK, etal |title=Harper's illustrated biochemistry |year=2012|publisher=McGraw-Hill Medical |isbn=978-0-07-176576-3 |edition=29th}} This increases the [[osmotic pressure]] of the urine and inhibits reabsorption of water by the kidney, resulting in increased urine production ([[polyuria]]) and increased fluid loss. Lost blood volume is replaced osmotically from water in body cells and other body compartments, causing [[dehydration]] and increased thirst ([[polydipsia]]). In addition, intracellular glucose deficiency stimulates appetite leading to excessive food intake (polyphagia).{{Cite book|title=Juta's Complete Textbook of Medical Surgical Nursing| vauthors = Mogotlane S |publisher=Juta|year=2013|location=Cape Town|pages=839}} [189] => [190] => ==Diagnosis== [191] => {{See also|Glycated hemoglobin|Glucose tolerance test}} [192] => [193] => Diabetes mellitus is diagnosed with a test for the glucose content in the blood, and is diagnosed by demonstrating any one of the following: [194] => * [[Fasting glucose|Fasting plasma glucose level]] ≥ 7.0 mmol/L (126 mg/dL). For this test, blood is taken after a period of fasting, i.e. in the morning before breakfast, after the patient had sufficient time to fast overnight or at least 8 hours before the test. [195] => * [[Plasma glucose]] ≥ 11.1 mmol/L (200 mg/dL) two hours after a 75 gram oral glucose load as in a [[glucose tolerance test]] (OGTT) [196] => * Symptoms of high blood sugar and plasma glucose ≥ 11.1 mmol/L (200 mg/dL) either while fasting or not fasting [197] => * [[Glycated hemoglobin]] (HbA1C) ≥ 48 mmol/mol (≥ 6.5 [[Diabetes control and complications trial|DCCT]] %).{{cite journal | vauthors = | title = Summary of revisions for the 2010 Clinical Practice Recommendations | journal = Diabetes Care | volume = 33 | issue = Suppl 1 | pages = S3 | date = January 2010 | pmid = 20042773 | pmc = 2797388 | doi = 10.2337/dc10-S003 | url = http://care.diabetesjournals.org/content/33/Supplement_1/S3.full | access-date = 29 January 2010 | url-status = live | archive-url = https://web.archive.org/web/20100113212053/http://care.diabetesjournals.org/content/33/Supplement_1/S3.full | archive-date = 13 January 2010 }} [198] => [199] => {{OGTT}} [200] => A positive result, in the absence of unequivocal high blood sugar, should be confirmed by a repeat of any of the above methods on a different day. It is preferable to measure a fasting glucose level because of the ease of measurement and the considerable time commitment of formal glucose tolerance testing, which takes two hours to complete and offers no prognostic advantage over the fasting test.{{cite journal | vauthors = Saydah SH, Miret M, Sung J, Varas C, Gause D, Brancati FL | title = Postchallenge hyperglycemia and mortality in a national sample of U.S. adults | journal = Diabetes Care | volume = 24 | issue = 8 | pages = 1397–1402 | date = August 2001 | pmid = 11473076 | doi = 10.2337/diacare.24.8.1397 | doi-access = free }} According to the current definition, two fasting glucose measurements at or above 7.0 mmol/L (126 mg/dL) is considered diagnostic for diabetes mellitus. [201] => [202] => Per the WHO, people with fasting glucose levels from 6.1 to 6.9 mmol/L (110 to 125 mg/dL) are considered to have [[impaired fasting glycemia|impaired fasting glucose]].{{cite book |title=Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: report of a WHO/IDF consultation |url=https://www.who.int/diabetes/publications/Definition%20and%20diagnosis%20of%20diabetes_new.pdf |publisher=World Health Organization |page=21 |year=2006 |isbn=978-92-4-159493-6 |url-status=live |archive-url=https://web.archive.org/web/20120511072821/http://www.who.int/diabetes/publications/Definition%20and%20diagnosis%20of%20diabetes_new.pdf |archive-date=11 May 2012}} People with plasma glucose at or above 7.8 mmol/L (140 mg/dL), but not over 11.1 mmol/L (200 mg/dL), two hours after a 75 gram oral glucose load are considered to have [[impaired glucose tolerance]]. Of these two prediabetic states, the latter in particular is a major risk factor for progression to full-blown diabetes mellitus, as well as cardiovascular disease.{{cite journal | vauthors = Santaguida PL, Balion C, Hunt D, Morrison K, Gerstein H, Raina P, Booker L, Yazdi H | display-authors = 6 | title = Diagnosis, prognosis, and treatment of impaired glucose tolerance and impaired fasting glucose | journal = Evidence Report/Technology Assessment | issue = 128 | pages = 1–11 | date = August 2005 | pmid = 16194123 | pmc = 4780988 | url = http://www.ahrq.gov/clinic/epcsums/impglusum.htm | access-date = 20 July 2008 | publisher = [[Agency for Healthcare Research and Quality]] | url-status = live | archive-url = https://web.archive.org/web/20080916030540/http://www.ahrq.gov/clinic/epcsums/impglusum.htm | archive-date = 16 September 2008 }} The [[American Diabetes Association]] (ADA) since 2003 uses a slightly different range for impaired fasting glucose of 5.6 to 6.9 mmol/L (100 to 125 mg/dL).{{cite journal | vauthors = Bartoli E, Fra GP, Carnevale Schianca GP | title = The oral glucose tolerance test (OGTT) revisited | journal = European Journal of Internal Medicine | volume = 22 | issue = 1 | pages = 8–12 | date = February 2011 | pmid = 21238885 | doi = 10.1016/j.ejim.2010.07.008 }} [203] => [204] => [[Glycated hemoglobin]] is better than [[fasting glucose]] for determining risks of cardiovascular disease and death from any cause.{{cite journal | vauthors = Selvin E, Steffes MW, Zhu H, Matsushita K, Wagenknecht L, Pankow J, Coresh J, Brancati FL | display-authors = 6 | title = Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults | journal = The New England Journal of Medicine | volume = 362 | issue = 9 | pages = 800–811 | date = March 2010 | pmid = 20200384 | pmc = 2872990 | doi = 10.1056/NEJMoa0908359 | citeseerx = 10.1.1.589.1658 }} [205] => [206] => ==Prevention== [207] => {{See also|Prevention of type 2 diabetes}} [208] => There is no known [[Preventive healthcare|preventive]] measure for type 1 diabetes. However, islet autoimmunity and multiple antibodies can be a strong predictor of the onset of type 1 diabetes.{{Cite journal |last1=Jacobsen |first1=Laura M. |last2=Haller |first2=Michael J. |last3=Schatz |first3=Desmond A. |date=2018-03-06 |title=Understanding Pre-Type 1 Diabetes: The Key to Prevention |journal= Frontiers in Endocrinology|volume=9 |page=70 |doi=10.3389/fendo.2018.00070 |pmid=29559955 |pmc=5845548 |doi-access=free }} Type 2 diabetes—which accounts for 85–90% of all cases worldwide—can often be prevented or delayed{{cite journal | vauthors = | title = Tackling risk factors for type 2 diabetes in adolescents: PRE-STARt study in Euskadi | journal = Anales de Pediatria | volume = 95 | issue = 3 | pages = 186–196 | date = 2020 | pmid = 33388268 | doi = 10.1016/j.anpedi.2020.11.001 | publisher = Anales de Pediatría | doi-access = free }} by maintaining a [[normal body weight]], engaging in physical activity, and eating a healthy diet. Higher levels of physical activity (more than 90 minutes per day) reduce the risk of diabetes by 28%.{{cite journal | vauthors = Kyu HH, Bachman VF, Alexander LT, Mumford JE, Afshin A, Estep K, Veerman JL, Delwiche K, Iannarone ML, Moyer ML, Cercy K, Vos T, Murray CJ, Forouzanfar MH | display-authors = 6 | title = Physical activity and risk of breast cancer, colon cancer, diabetes, ischemic heart disease, and ischemic stroke events: systematic review and dose-response meta-analysis for the Global Burden of Disease Study 2013 | journal = BMJ | volume = 354 | pages = i3857 | date = August 2016 | pmid = 27510511 | pmc = 4979358 | doi = 10.1136/bmj.i3857 }} Dietary changes known to be effective in helping to prevent diabetes include maintaining a diet rich in [[whole grain]]s and [[Dietary fiber|fiber]], and choosing good fats, such as the [[polyunsaturated fat]]s found in nuts, vegetable oils, and fish.{{cite web|website=The Nutrition Source|title = Simple Steps to Preventing Diabetes |date = 18 September 2012 |url=http://www.hsph.harvard.edu/nutritionsource/preventing-diabetes-full-story/#references |publisher= Harvard T.H. Chan School of Public Health|url-status=live|archive-url=https://web.archive.org/web/20140425020720/http://www.hsph.harvard.edu/nutritionsource/preventing-diabetes-full-story/#references|archive-date=25 April 2014}} Limiting sugary beverages and eating less red meat and other sources of [[saturated fat]] can also help prevent diabetes. Tobacco smoking is also associated with an increased risk of diabetes and its complications, so [[smoking cessation]] can be an important preventive measure as well.{{cite journal | vauthors = Willi C, Bodenmann P, Ghali WA, Faris PD, Cornuz J | title = Active smoking and the risk of type 2 diabetes: a systematic review and meta-analysis | journal = JAMA | volume = 298 | issue = 22 | pages = 2654–2664 | date = December 2007 | pmid = 18073361 | doi = 10.1001/jama.298.22.2654 | s2cid = 30550981 }} [209] => [210] => The relationship between type 2 diabetes and the main modifiable risk factors (excess weight, unhealthy diet, physical inactivity and tobacco use) is similar in all regions of the world. There is growing evidence that the underlying determinants of diabetes are a reflection of the major forces driving social, economic and cultural change: [[globalization]], urbanization, population aging, and the general [[health policy]] environment.{{cite web |publisher=World Health Organization |url=https://www.who.int/chp/chronic_disease_report/media/Factsheet1.pdf |title=Chronic diseases and their common risk factors |url-status=live |archive-url=https://web.archive.org/web/20161017172040/http://www.who.int/chp/chronic_disease_report/media/Factsheet1.pdf |archive-date=2016-10-17 |date=2005 |access-date=30 August 2016}} [211] => [212] => == Comorbidity == [213] => Diabetes patients' comorbidities have a significant impact on medical expenses and related costs. It has been demonstrated that patients with diabetes are more likely to experience respiratory, urinary tract, and skin infections, develop atherosclerosis, hypertension, and chronic kidney disease, putting them at increased risk of infection and complications that require medical attention.{{Cite web |last=CDC |date=2023-07-31 |title=Diabetes and Your Immune System |url=https://www.cdc.gov/diabetes/library/features/diabetes_immune_system.html |access-date=2024-04-25 |website=Centers for Disease Control and Prevention }} Patients with diabetes mellitus are more likely to experience certain infections, such as COVID-19, with prevalence rates ranging from 5.3 to 35.5%.{{Cite journal |last=Singh |first=Awadhesh Kumar |last2=Gupta |first2=Ritesh |last3=Ghosh |first3=Amerta |last4=Misra |first4=Anoop |date=2020 |title=Diabetes in COVID-19: Prevalence, pathophysiology, prognosis and practical considerations |url=https://pubmed.ncbi.nlm.nih.gov/32298981/ |journal=Diabetes & Metabolic Syndrome |volume=14 |issue=4 |pages=303–310 |doi=10.1016/j.dsx.2020.04.004 |issn=1878-0334 |pmc=7195120 |pmid=32298981}}{{Cite journal |last=Abdelhafiz |first=Ahmed H. |last2=Emmerton |first2=Demelza |last3=Sinclair |first3=Alan J. |date=July 2021 |title=Diabetes in COVID-19 pandemic-prevalence, patient characteristics and adverse outcomes |url=https://pubmed.ncbi.nlm.nih.gov/33630378/ |journal=International Journal of Clinical Practice |volume=75 |issue=7 |pages=e14112 |doi=10.1111/ijcp.14112 |issn=1742-1241 |pmc=7995213 |pmid=33630378}} Maintaining adequate glycemic control is the primary goal of diabetes management since it is critical to managing diabetes and preventing or postponing such complications.{{Cite journal |date=1998-09-12 |title=Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group |url=https://pubmed.ncbi.nlm.nih.gov/9742976/ |journal=Lancet (London, England) |volume=352 |issue=9131 |pages=837–853 |issn=0140-6736 |pmid=9742976}} [214] => [215] => ==Management== [216] => {{Main|Diabetes management}} [217] => Diabetes management concentrates on keeping blood sugar levels close to normal, without causing low blood sugar.{{cite web |title=Managing diabetes |url=https://www.niddk.nih.gov/health-information/diabetes/overview/managing-diabetes |publisher=National Institute of Diabetes and Digestive and Kidney Diseases, US National Institutes of Health |access-date=4 February 2023 |date=1 December 2016 |archive-date=6 March 2023 |archive-url=https://web.archive.org/web/20230306044924/https://www.niddk.nih.gov/health-information/diabetes/overview/managing-diabetes |url-status=live }} This can usually be accomplished with dietary changes,{{cite journal | vauthors = Toumpanakis A, Turnbull T, Alba-Barba I | title = Effectiveness of plant-based diets in promoting well-being in the management of type 2 diabetes: a systematic review | journal = BMJ Open Diabetes Research & Care | volume = 6 | issue = 1 | pages = e000534 | date = 2018-10-30 | pmid = 30487971 | pmc = 6235058 | doi = 10.1136/bmjdrc-2018-000534 }} exercise, weight loss, and use of appropriate medications (insulin, oral medications). [218] => [219] => Learning about the disease and actively participating in the treatment is important, since complications are far less common and less severe in people who have well-managed blood sugar levels.{{cite journal|title = The effect of intensive diabetes therapy on the development and progression of neuropathy|author=The Diabetes Control and Complications Trial Research Group | journal = Annals of Internal Medicine | volume = 122 | issue = 8 | pages = 561–568 | date = April 1995 | pmid = 7887548 | doi = 10.7326/0003-4819-122-8-199504150-00001 | s2cid = 24754081 }} The goal of treatment is an A1C level below 7%.{{cite web |title=The A1C test and diabetes |url=https://www.niddk.nih.gov/health-information/diagnostic-tests/a1c-test |publisher=National Institute of Diabetes and Digestive and Kidney Diseases, US National Institutes of Health |access-date=4 February 2023 |date=1 April 2018 |archive-date=4 February 2023 |archive-url=https://web.archive.org/web/20230204214740/https://www.niddk.nih.gov/health-information/diagnostic-tests/a1c-test |url-status=live }}{{cite journal |display-authors=3| vauthors = Qaseem A, Wilt TJ, Kansagara D, Horwitch C, Barry MJ, Forciea MA, Fitterman N, Balzer K, Boyd C, Humphrey LL, Iorio A, Lin J, Maroto M, McLean R, Mustafa R, Tufte J | title = Hemoglobin A1c Targets for Glycemic Control With Pharmacologic Therapy for Nonpregnant Adults With Type 2 Diabetes Mellitus: A Guidance Statement Update From the American College of Physicians | journal = Annals of Internal Medicine | volume = 168 | issue = 8 | pages = 569–576 | date = April 2018 | pmid = 29507945 | doi = 10.7326/M17-0939 | doi-access = free }} Attention is also paid to other health problems that may accelerate the negative effects of diabetes. These include [[tobacco smoking|smoking]], [[hypertension|high blood pressure]], [[metabolic syndrome]] [[obesity]], and lack of regular [[exercise]].{{NICE|66|Type 2 diabetes|2008}} [[Diabetic shoe|Specialized footwear]] is widely used to reduce the risk of [[diabetic foot ulcer]]s by relieving the pressure on the foot.{{cite journal | vauthors = Bus SA, van Deursen RW, Armstrong DG, Lewis JE, Caravaggi CF, Cavanagh PR | title = Footwear and offloading interventions to prevent and heal foot ulcers and reduce plantar pressure in patients with diabetes: a systematic review | journal = Diabetes/Metabolism Research and Reviews | volume = 32 | issue = Suppl 1 | pages = 99–118 | date = January 2016 | pmid = 26342178 | doi = 10.1002/dmrr.2702 | s2cid = 24862853 | doi-access = free }}{{cite journal | vauthors = Heuch L, Streak Gomersall J | title = Effectiveness of offloading methods in preventing primary diabetic foot ulcers in adults with diabetes: a systematic review | journal = JBI Database of Systematic Reviews and Implementation Reports | volume = 14 | issue = 7 | pages = 236–265 | date = July 2016 | pmid = 27532798 | doi = 10.11124/JBISRIR-2016-003013 | s2cid = 12012686 }}{{cite journal | vauthors = van Netten JJ, Raspovic A, Lavery LA, Monteiro-Soares M, Rasmussen A, Sacco IC, Bus SA | title = Prevention of foot ulcers in the at-risk patient with diabetes: a systematic review | journal = Diabetes/Metabolism Research and Reviews | volume = 36 | issue = S1 Suppl 1 | pages = e3270 | date = March 2020 | pmid = 31957213 | doi = 10.1002/dmrr.3270 | s2cid = 210830578 | url = https://eprints.qut.edu.au/220879/1/Van%2BNetten%2Bet%2Bal%2B-%2B2016%2B-%2BPrevention%2Bof%2Bfoot%2Bulcers%2Bsystematic%2Breview.pdf | access-date = 2023-01-23 | archive-date = 2023-02-09 | archive-url = https://web.archive.org/web/20230209225712/https://eprints.qut.edu.au/220879/1/Van%2BNetten%2Bet%2Bal%2B-%2B2016%2B-%2BPrevention%2Bof%2Bfoot%2Bulcers%2Bsystematic%2Breview.pdf | url-status = live }} Foot examination for patients living with diabetes should be done annually which includes sensation testing, foot [[biomechanics]], vascular integrity and foot structure.{{cite journal | vauthors = Mayfield JA, Reiber GE, Sanders LJ, Janisse D, Pogach LM | title = Preventive foot care in diabetes | journal = Diabetes Care | volume = 27 | issue = suppl_1 | pages = S63–S64 | date = January 2004 | pmid = 14693928 | doi = 10.2337/diacare.27.2007.S63 | doi-access = free }} [220] => [221] => Concerning those with severe [[Mental disorder|mental illness]], the efficacy of [[type 2 diabetes]] self-management interventions is still poorly explored, with insufficient scientific evidence to show whether these interventions have similar results to those observed in the general population.{{cite journal | vauthors = McBain H, Mulligan K, Haddad M, Flood C, Jones J, Simpson A | title = Self management interventions for type 2 diabetes in adult people with severe mental illness | journal = The Cochrane Database of Systematic Reviews | volume = 2016 | pages = CD011361 | date = April 2016 | issue = 4 | pmid = 27120555 | doi = 10.1002/14651858.CD011361.pub2 | collaboration = Cochrane Metabolic and Endocrine Disorders Group | pmc = 10201333 }} [222] => [223] => ===Lifestyle=== [224] => {{See also|Diet in diabetes}} [225] => People with diabetes can benefit from education about the disease and treatment, dietary changes, and exercise, with the goal of keeping both short-term and long-term blood glucose levels [[Diabetes management#Glycemic control|within acceptable bounds]]. In addition, given the associated higher risks of cardiovascular disease, lifestyle modifications are recommended to control blood pressure.{{cite journal | vauthors = Haw JS, Galaviz KI, Straus AN, Kowalski AJ, Magee MJ, Weber MB, Wei J, Narayan KM, Ali MK | display-authors = 3 | title = Long-term Sustainability of Diabetes Prevention Approaches: A Systematic Review and Meta-analysis of Randomized Clinical Trials | journal = JAMA Internal Medicine | volume = 177 | issue = 12 | pages = 1808–1817 | date = December 2017 | pmid = 29114778 | pmc = 5820728 | doi = 10.1001/jamainternmed.2017.6040 }}{{cite journal | vauthors = Mottalib A, Kasetty M, Mar JY, Elseaidy T, Ashrafzadeh S, Hamdy O | title = Weight Management in Patients with Type 1 Diabetes and Obesity | journal = Current Diabetes Reports | volume = 17 | issue = 10 | pages = 92 | date = August 2017 | pmid = 28836234 | pmc = 5569154 | doi = 10.1007/s11892-017-0918-8 }} [226] => [227] => [[Weight loss]] can prevent progression from prediabetes to [[Diabetes mellitus|diabetes type 2]], decrease the risk of cardiovascular disease, or result in a partial remission in people with diabetes.{{cite journal | title = 5. Lifestyle Management: ''Standards of Medical Care in Diabetes-2019'' | journal = Diabetes Care | volume = 42 | issue = Suppl 1 | pages = S46–S60 | date = January 2019 | pmid = 30559231 | doi = 10.2337/dc19-S005 | doi-access = free | author1 = American Diabetes Association }}{{cite journal | vauthors = Evert AB, Dennison M, Gardner CD, Garvey WT, Lau KH, MacLeod J, Mitri J, Pereira RF, Rawlings K, Robinson S, Saslow L, Uelmen S, Urbanski PB, Yancy WS | display-authors = 3 | title = Nutrition Therapy for Adults With Diabetes or Prediabetes: A Consensus Report | journal = Diabetes Care | volume = 42 | issue = 5 | pages = 731–754 | date = May 2019 | pmid = 31000505 | pmc = 7011201 | doi = 10.2337/dci19-0014 | type = Professional society guidelines | doi-access = free }} No single dietary pattern is best for all people with diabetes. Healthy dietary patterns, such as the [[Mediterranean diet]], [[low-carbohydrate diet]], or [[DASH diet]], are often recommended, although evidence does not support one over the others. According to the ADA, "reducing overall carbohydrate intake for individuals with diabetes has demonstrated the most evidence for improving glycemia", and for individuals with type 2 diabetes who cannot meet the glycemic targets or where reducing anti-glycemic medications is a priority, [[low-carbohydrate diet|low or very-low carbohydrate diet]]s are a viable approach. For overweight people with type 2 diabetes, any diet that achieves weight loss is effective.{{cite journal | vauthors = Emadian A, Andrews RC, England CY, Wallace V, Thompson JL | title = The effect of macronutrients on glycaemic control: a systematic review of dietary randomised controlled trials in overweight and obese adults with type 2 diabetes in which there was no difference in weight loss between treatment groups | journal = The British Journal of Nutrition | volume = 114 | issue = 10 | pages = 1656–1666 | date = November 2015 | pmid = 26411958 | pmc = 4657029 | doi = 10.1017/S0007114515003475 }}{{cite journal | vauthors = Grams J, Garvey WT | title = Weight Loss and the Prevention and Treatment of Type 2 Diabetes Using Lifestyle Therapy, Pharmacotherapy, and Bariatric Surgery: Mechanisms of Action | journal = Current Obesity Reports | volume = 4 | issue = 2 | pages = 287–302 | date = June 2015 | pmid = 26627223 | doi = 10.1007/s13679-015-0155-x | s2cid = 207474124 }} [228] => [229] => A 2020 Cochrane systematic review compared several non-nutritive sweeteners to sugar, placebo and a nutritive low-calorie sweetener ([[tagatose]]), but the results were unclear for effects on HbA1c, body weight and adverse events.{{Cite journal |last1=Lohner |first1=Szimonetta |last2=Kuellenberg de Gaudry |first2=Daniela |last3=Toews |first3=Ingrid |last4=Ferenci |first4=Tamas |last5=Meerpohl |first5=Joerg J |date=2020-05-25 |editor-last=Cochrane Metabolic and Endocrine Disorders Group |title=Non-nutritive sweeteners for diabetes mellitus |journal=Cochrane Database of Systematic Reviews |volume=2020 |issue=5 |pages=CD012885 |doi=10.1002/14651858.CD012885.pub2 |pmc=7387865 |pmid=32449201}} The studies included were mainly of very low-certainty and did not report on health-related quality of life, diabetes complications, all-cause mortality or socioeconomic effects. [230] => [231] => ===Medications=== [232] => {{Main|Diabetes medication}} [233] => [234] => ====Glucose control==== [235] => {{see also|Anti-diabetic medication}} [236] => Most medications used to treat diabetes act by lowering [[glucose|blood sugar levels]] through different mechanisms. There is broad consensus that when people with diabetes maintain tight glucose control – keeping the glucose levels in their blood within normal ranges – they experience fewer complications, such as [[diabetic nephropathy|kidney problems]] or [[diabetic retinopathy|eye problems]].{{cite journal | vauthors = Rosberger DF | title = Diabetic retinopathy: current concepts and emerging therapy | journal = Endocrinology and Metabolism Clinics of North America | volume = 42 | issue = 4 | pages = 721–745 | date = December 2013 | pmid = 24286948 | doi = 10.1016/j.ecl.2013.08.001 }}{{cite journal | vauthors = MacIsaac RJ, Jerums G, Ekinci EI | title = Glycemic Control as Primary Prevention for Diabetic Kidney Disease | journal = Advances in Chronic Kidney Disease | volume = 25 | issue = 2 | pages = 141–148 | date = March 2018 | pmid = 29580578 | doi = 10.1053/j.ackd.2017.11.003 }} There is however debate as to whether this is appropriate and [[cost effective]] for people later in life in whom the risk of hypoglycemia may be more significant.{{cite journal | vauthors = Pozzilli P, Strollo R, Bonora E | title = One size does not fit all glycemic targets for type 2 diabetes | journal = Journal of Diabetes Investigation | volume = 5 | issue = 2 | pages = 134–141 | date = March 2014 | pmid = 24843750 | pmc = 4023573 | doi = 10.1111/jdi.12206 }} [237] => [238] => There are a number of different classes of anti-diabetic medications. Type 1 diabetes requires treatment with [[insulin]], ideally using a "basal bolus" regimen that most closely matches normal insulin release: long-acting insulin for the [[basal rate]] and short-acting insulin with meals.{{cite web |title=Type 1 diabetes in adults: diagnosis and management |url=https://www.nice.org.uk/guidance/ng17 |website=www.nice.org.uk |publisher=National Institute for Health and Care Excellence |date=26 August 2015 |access-date=25 December 2020 |archive-date=10 December 2020 |archive-url=https://web.archive.org/web/20201210211840/https://www.nice.org.uk/guidance/NG17 |url-status=live }} Type 2 diabetes is generally treated with medication that is taken by mouth (e.g. [[metformin]]) although some eventually require injectable treatment with insulin or [[GLP-1 agonist]]s.{{cite web |title=Type 2 diabetes in adults: management |url=https://www.nice.org.uk/guidance/ng28 |website=www.nice.org.uk |publisher=National Institute for Health and Care Excellence |date=2 December 2015 |access-date=25 December 2020 |archive-date=22 December 2020 |archive-url=https://web.archive.org/web/20201222155551/https://www.nice.org.uk/guidance/ng28 |url-status=live }} [239] => [240] => [[Metformin]] is generally recommended as a first-line treatment for type 2 diabetes, as there is good evidence that it decreases mortality.{{cite journal | vauthors = Ripsin CM, Kang H, Urban RJ | title = Management of blood glucose in type 2 diabetes mellitus | journal = American Family Physician | volume = 79 | issue = 1 | pages = 29–36 | date = January 2009 | pmid = 19145963 | url = http://www.aafp.org/afp/2009/0101/p29.pdf | url-status = live | archive-url = https://web.archive.org/web/20130505033552/http://www.aafp.org/afp/2009/0101/p29.pdf | archive-date = 2013-05-05 }} It works by decreasing the liver's production of glucose, and increasing the amount of glucose stored in peripheral tissue.{{cite journal | vauthors = Krentz AJ, Bailey CJ | title = Oral antidiabetic agents: current role in type 2 diabetes mellitus | journal = Drugs | volume = 65 | issue = 3 | pages = 385–411 | date = 2005 | pmid = 15669880 | doi = 10.2165/00003495-200565030-00005 | s2cid = 29670619 }} Several other groups of drugs, mainly oral medication, may also decrease blood sugar in type 2 diabetes. These include agents that increase insulin release ([[sulfonylurea]]s), agents that decrease absorption of sugar from the intestines ([[acarbose]]), agents that inhibit the enzyme dipeptidyl peptidase-4 (DPP-4) that inactivates incretins such as GLP-1 and GIP ([[sitagliptin]]), agents that make the body more sensitive to insulin ([[thiazolidinedione]]) and agents that increase the excretion of glucose in the urine ([[SGLT2 inhibitor]]s). When insulin is used in type 2 diabetes, a long-acting formulation is usually added initially, while continuing oral medications. [241] => [242] => Some severe cases of type 2 diabetes may also be treated with insulin, which is increased gradually until glucose targets are reached.{{Citation| author1 = Consumer Reports| author2-link = American College of Physicians| author2 = American College of Physicians| date = April 2012| title = Choosing a type 2 diabetes drug – Why the best first choice is often the oldest drug| publisher = [[Consumer Reports]]| work = High Value Care| url = http://consumerhealthchoices.org/wp-content/uploads/2012/04/High-Value-Care-Diabetes-ACP.pdf| access-date = August 14, 2012| url-status=live| archive-url = https://web.archive.org/web/20140702223552/http://consumerhealthchoices.org/wp-content/uploads/2012/04/High-Value-Care-Diabetes-ACP.pdf| archive-date = July 2, 2014| author1-link = Consumer Reports}} [243] => [244] => ====Blood pressure lowering==== [245] => [[Cardiovascular disease]] is a serious complication associated with diabetes, and many international guidelines recommend blood pressure treatment targets that are lower than 140/90 mmHg for people with diabetes.{{cite journal | vauthors = Mitchell S, Malanda B, Damasceno A, Eckel RH, Gaita D, Kotseva K, Januzzi JL, Mensah G, Plutzky J, Prystupiuk M, Ryden L, Thierer J, Virani SS, Sperling L | display-authors = 3 | title = A Roadmap on the Prevention of Cardiovascular Disease Among People Living With Diabetes | journal = Global Heart | volume = 14 | issue = 3 | pages = 215–240 | date = September 2019 | pmid = 31451236 | doi = 10.1016/j.gheart.2019.07.009 | doi-access = free }} However, there is only limited evidence regarding what the lower targets should be. A 2016 systematic review found potential harm to treating to targets lower than 140 mmHg,{{cite journal | vauthors = Brunström M, Carlberg B | title = Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses | journal = BMJ | volume = 352 | pages = i717 | date = February 2016 | pmid = 26920333 | pmc = 4770818 | doi = 10.1136/bmj.i717 }} and a subsequent systematic review in 2019 found no evidence of additional benefit from blood pressure lowering to between 130 – 140mmHg, although there was an increased risk of adverse events.{{cite journal | vauthors = Brunström M, Carlberg B | title = Benefits and harms of lower blood pressure treatment targets: systematic review and meta-analysis of randomised placebo-controlled trials | journal = BMJ Open | volume = 9 | issue = 9 | pages = e026686 | date = September 2019 | pmid = 31575567 | pmc = 6773352 | doi = 10.1136/bmjopen-2018-026686 }} [246] => [247] => 2015 American Diabetes Association recommendations are that people with diabetes and albuminuria should receive an inhibitor of the renin-angiotensin system to reduce the risks of progression to end-stage renal disease, cardiovascular events, and death.{{cite journal | vauthors = Fox CS, Golden SH, Anderson C, Bray GA, Burke LE, de Boer IH, Deedwania P, Eckel RH, Ershow AG, Fradkin J, Inzucchi SE, Kosiborod M, Nelson RG, Patel MJ, Pignone M, Quinn L, Schauer PR, Selvin E, Vafiadis DK | display-authors = 3 | title = Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association | journal = Diabetes Care | volume = 38 | issue = 9 | pages = 1777–1803 | date = September 2015 | pmid = 26246459 | pmc = 4876675 | doi = 10.2337/dci15-0012 }} There is some evidence that [[angiotensin converting enzyme inhibitors]] (ACEIs) are superior to other inhibitors of the renin-angiotensin system such as [[angiotensin receptor blockers]] (ARBs),{{cite journal | vauthors = Cheng J, Zhang W, Zhang X, Han F, Li X, He X, Li Q, Chen J | display-authors = 3 | title = Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis | journal = JAMA Internal Medicine | volume = 174 | issue = 5 | pages = 773–785 | date = May 2014 | pmid = 24687000 | doi = 10.1001/jamainternmed.2014.348 | doi-access = free }} or [[aliskiren]] in preventing cardiovascular disease.{{cite journal | vauthors = Zheng SL, Roddick AJ, Ayis S | title = Effects of aliskiren on mortality, cardiovascular outcomes and adverse events in patients with diabetes and cardiovascular disease or risk: A systematic review and meta-analysis of 13,395 patients | journal = Diabetes & Vascular Disease Research | volume = 14 | issue = 5 | pages = 400–406 | date = September 2017 | pmid = 28844155 | pmc = 5600262 | doi = 10.1177/1479164117715854 }} Although a more recent review found similar effects of ACEIs and ARBs on major cardiovascular and renal outcomes.{{cite journal | vauthors = Catalá-López F, Macías Saint-Gerons D, González-Bermejo D, Rosano GM, Davis BR, Ridao M, Zaragoza A, Montero-Corominas D, Tobías A, de la Fuente-Honrubia C, Tabarés-Seisdedos R, Hutton B |author5-link=Barry R. Davis| display-authors = 3 | title = Cardiovascular and Renal Outcomes of Renin-Angiotensin System Blockade in Adult Patients with Diabetes Mellitus: A Systematic Review with Network Meta-Analyses | journal = PLOS Medicine | volume = 13 | issue = 3 | pages = e1001971 | date = March 2016 | pmid = 26954482 | pmc = 4783064 | doi = 10.1371/journal.pmed.1001971 |doi-access=free }} There is no evidence that combining ACEIs and ARBs provides additional benefits. [248] => [249] => ==== Aspirin ==== [250] => The use of [[aspirin]] to prevent cardiovascular disease in diabetes is controversial. Aspirin is recommended by some in people at high risk of cardiovascular disease, however routine use of aspirin has not been found to improve outcomes in uncomplicated diabetes.{{cite journal | vauthors = Pignone M, Alberts MJ, Colwell JA, Cushman M, Inzucchi SE, Mukherjee D, Rosenson RS, Williams CD, Wilson PW, Kirkman MS | display-authors = 3 | title = Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation | journal = Diabetes Care | volume = 33 | issue = 6 | pages = 1395–1402 | date = June 2010 | pmid = 20508233 | pmc = 2875463 | doi = 10.2337/dc10-0555 }} 2015 American Diabetes Association recommendations for aspirin use (based on expert consensus or clinical experience) are that low-dose aspirin use is reasonable in adults with diabetes who are at intermediate risk of cardiovascular disease (10-year cardiovascular disease risk, 5–10%). National guidelines for England and Wales by the [[National Institute for Health and Care Excellence]] (NICE) recommend against the use of aspirin in people with type 1 or type 2 diabetes who do not have confirmed cardiovascular disease. [251] => [252] => ===Surgery=== [253] => [[Bariatric surgery|Weight loss surgery]] in those with [[obesity]] and type 2 diabetes is often an effective measure.{{cite journal |vauthors=Picot J, Jones J, Colquitt JL, Gospodarevskaya E, Loveman E, Baxter L, Clegg AJ |date=September 2009 |title=The clinical effectiveness and cost-effectiveness of bariatric (weight loss) surgery for obesity: a systematic review and economic evaluation |journal=Health Technology Assessment |volume=13 |issue=41 |pages=1–190, 215–357, iii–iv |doi=10.3310/hta13410 |pmid=19726018 |doi-access=free |hdl=10536/DRO/DU:30064294|hdl-access=free }} Many are able to maintain normal blood sugar levels with little or no medications following surgery{{cite journal | vauthors = Frachetti KJ, Goldfine AB | title = Bariatric surgery for diabetes management | journal = Current Opinion in Endocrinology, Diabetes and Obesity | volume = 16 | issue = 2 | pages = 119–124 | date = April 2009 | pmid = 19276974 | doi = 10.1097/MED.0b013e32832912e7 | s2cid = 31797748 | doi-access = free }} and long-term mortality is decreased. There is, however, a short-term mortality risk of less than 1% from the surgery.{{cite journal | vauthors = Colucci RA | title = Bariatric surgery in patients with type 2 diabetes: a viable option | journal = Postgraduate Medicine | volume = 123 | issue = 1 | pages = 24–33 | date = January 2011 | pmid = 21293081 | doi = 10.3810/pgm.2011.01.2242 | s2cid = 207551737 }} The [[body mass index]] cutoffs for when surgery is appropriate are not yet clear.{{cite journal | vauthors = Schulman AP, del Genio F, Sinha N, Rubino F | title = "Metabolic" surgery for treatment of type 2 diabetes mellitus | journal = Endocrine Practice | volume = 15 | issue = 6 | pages = 624–631 | date = September–October 2009 | pmid = 19625245 | doi = 10.4158/EP09170.RAR }} It is recommended that this option be considered in those who are unable to get both their weight and blood sugar under control.{{cite journal | vauthors = Dixon JB, le Roux CW, Rubino F, Zimmet P | title = Bariatric surgery for type 2 diabetes | journal = Lancet | volume = 379 | issue = 9833 | pages = 2300–2311 | date = June 2012 | pmid = 22683132 | doi = 10.1016/S0140-6736(12)60401-2 | s2cid = 5198462 }} [254] => [255] => A [[pancreas transplant]] is occasionally considered for people with type 1 diabetes who have severe complications of their disease, including [[Chronic kidney disease|end stage kidney disease]] requiring [[kidney transplantation]].{{cite web|title=Pancreas Transplantation|url=http://www.diabetes.org/living-with-diabetes/treatment-and-care/transplantation/pancreas-transplantation.html|publisher=American Diabetes Association|access-date=9 April 2014|url-status=dead|archive-url=https://web.archive.org/web/20140413123750/http://www.diabetes.org/living-with-diabetes/treatment-and-care/transplantation/pancreas-transplantation.html|archive-date=13 April 2014}} [256] => [257] => ===Self-management and support=== [258] => In countries using a [[general practitioner]] system, such as the United Kingdom, care may take place mainly outside hospitals, with hospital-based specialist care used only in case of complications, difficult blood sugar control, or research projects. In other circumstances, general practitioners and specialists share care in a team approach. Evidence has shown that social prescribing led to slight improvements in blood sugar control for people with type 2 diabetes.{{Cite journal |title=Can social prescribing improve the health of people with diabetes? |url=https://evidence.nihr.ac.uk/alert/can-social-prescribing-improve-the-health-of-people-with-diabetes/ |access-date=26 January 2024 |website=National Institute for Health and Care Research - NIHR Evidence |date=2024 |doi=10.3310/nihrevidence_61876 |s2cid=267264134 |archive-date=26 January 2024 |archive-url=https://web.archive.org/web/20240126130722/https://evidence.nihr.ac.uk/alert/can-social-prescribing-improve-the-health-of-people-with-diabetes/ |url-status=live }} Home [[telehealth]] support can be an effective management technique.{{cite journal | vauthors = Polisena J, Tran K, Cimon K, Hutton B, McGill S, Palmer K | title = Home telehealth for diabetes management: a systematic review and meta-analysis | journal = Diabetes, Obesity & Metabolism | volume = 11 | issue = 10 | pages = 913–930 | date = October 2009 | pmid = 19531058 | doi = 10.1111/j.1463-1326.2009.01057.x | s2cid = 44260857 }} [259] => [260] => The use of [[technology]] to deliver educational programs for adults with type 2 diabetes includes computer-based self-management interventions to collect for tailored responses to facilitate self-management.{{cite journal | vauthors = Pal K, Eastwood SV, Michie S, Farmer AJ, Barnard ML, Peacock R, Wood B, Inniss JD, Murray E | display-authors = 3 | title = Computer-based diabetes self-management interventions for adults with type 2 diabetes mellitus | journal = The Cochrane Database of Systematic Reviews | issue = 3 | pages = CD008776 | date = March 2013 | volume = 2013 | pmid = 23543567 | pmc = 6486319 | doi = 10.1002/14651858.CD008776.pub2 | collaboration = Cochrane Metabolic and Endocrine Disorders Group }} There is no adequate evidence to support effects on [[cholesterol]], [[blood pressure]], [[Behavior change (public health)|behavioral change]] (such as [[physical activity]] levels and dietary), [[Depression (mood)|depression]], weight and [[Quality of life (healthcare)|health-related quality of life]], nor in other biological, cognitive or emotional outcomes.{{cite journal | vauthors = Wei I, Pappas Y, Car J, Sheikh A, Majeed A | title = Computer-assisted versus oral-and-written dietary history taking for diabetes mellitus | journal = The Cochrane Database of Systematic Reviews | issue = 12 | pages = CD008488 | date = December 2011 | volume = 2011 | pmid = 22161430 | pmc = 6486022 | doi = 10.1002/14651858.CD008488.pub2 | collaboration = Cochrane Metabolic and Endocrine Disorders Group }} [261] => [262] => ==Epidemiology== [263] => {{Main|Epidemiology of diabetes}} [264] => [[File:Prevalence of Diabetes by Percent of Country Population (2014) Gradient Map.png|thumb|upright=1.4|Rates of diabetes worldwide in 2014. The worldwide prevalence was 9.2%.]] [265] => [[File:Diabetes mellitus world map-Deaths per million persons-WHO2012.svg|thumb|upright=1.4|Mortality rate of diabetes worldwide in 2012 per million inhabitants {{Div col|small=yes|colwidth=10em}}{{legend|#ffff20|28–91}}{{legend|#ffe820|92–114}}{{legend|#ffd820|115–141}}{{legend|#ffc020|142–163}}{{legend|#ffa020|164–184}}{{legend|#ff9a20|185–209}}{{legend|#f08015|210–247}}{{legend|#e06815|248–309}}{{legend|#d85010|310–404}}{{legend|#d02010|405–1879}}{{div col end}}]] [266] => [267] => In 2017, 425 million people had diabetes worldwide,{{cite book|vauthors=Elflein J|url=https://www.statista.com/statistics/271442/number-of-diabetics-worldwide/|title=Estimated number diabetics worldwide|date=10 December 2019|access-date=17 May 2020|archive-date=29 July 2020|archive-url=https://web.archive.org/web/20200729234033/https://www.statista.com/statistics/271442/number-of-diabetics-worldwide/|url-status=live}} up from an estimated 382 million people in 2013{{cite journal | vauthors = Shi Y, Hu FB | title = The global implications of diabetes and cancer | journal = Lancet | volume = 383 | issue = 9933 | pages = 1947–1948 | date = June 2014 | pmid = 24910221 | doi = 10.1016/S0140-6736(14)60886-2 | s2cid = 7496891 }} and from 108 million in 1980.{{cite web |title=Global Report on Diabetes |publisher=World Health Organization |url=http://apps.who.int/iris/bitstream/handle/10665/204871/9789241565257_eng.pdf |access-date=20 September 2018 |date=2016 |archive-date=16 May 2018 |archive-url=https://web.archive.org/web/20180516185526/http://apps.who.int/iris/bitstream/handle/10665/204871/9789241565257_eng.pdf |url-status=live }} Accounting for the shifting age structure of the global population, the prevalence of diabetes is 8.8% among adults, nearly double the rate of 4.7% in 1980. Type 2 makes up about 90% of the cases.{{cite journal | vauthors = Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, Shibuya K, Salomon JA, Abdalla S, Aboyans V, Abraham J, Ackerman I, Aggarwal R, Ahn SY, Ali MK, Alvarado M, Anderson HR, Anderson LM, Andrews KG, Atkinson C, Baddour LM, Bahalim AN, Barker-Collo S, Barrero LH, Bartels DH, Basáñez MG, Baxter A, Bell ML, Benjamin EJ, Bennett D, Bernabé E, Bhalla K, Bhandari B, Bikbov B, Bin Abdulhak A, Birbeck G, Black JA, Blencowe H, Blore JD, Blyth F, Bolliger I, Bonaventure A, Boufous S, Bourne R, Boussinesq M, Braithwaite T, Brayne C, Bridgett L, Brooker S, Brooks P, Brugha TS, Bryan-Hancock C, Bucello C, Buchbinder R, Buckle G, Budke CM, Burch M, Burney P, Burstein R, Calabria B, Campbell B, Canter CE, Carabin H, Carapetis J, Carmona L, Cella C, Charlson F, Chen H, Cheng AT, Chou D, Chugh SS, Coffeng LE, Colan SD, Colquhoun S, Colson KE, Condon J, Connor MD, Cooper LT, Corriere M, Cortinovis M, de Vaccaro KC, Couser W, Cowie BC, Criqui MH, Cross M, Dabhadkar KC, Dahiya M, Dahodwala N, Damsere-Derry J, Danaei G, Davis A, De Leo D, Degenhardt L, Dellavalle R, Delossantos A, Denenberg J, Derrett S, Des Jarlais DC, Dharmaratne SD, Dherani M, Diaz-Torne C, Dolk H, Dorsey ER, Driscoll T, Duber H, Ebel B, Edmond K, Elbaz A, Ali SE, Erskine H, Erwin PJ, Espindola P, Ewoigbokhan SE, Farzadfar F, Feigin V, Felson DT, Ferrari A, Ferri CP, Fèvre EM, Finucane MM, Flaxman S, Flood L, Foreman K, Forouzanfar MH, Fowkes FG, Franklin R, Fransen M, Freeman MK, Gabbe BJ, Gabriel SE, Gakidou E, Ganatra HA, Garcia B, Gaspari F, Gillum RF, Gmel G, Gosselin R, Grainger R, Groeger J, Guillemin F, Gunnell D, Gupta R, Haagsma J, Hagan H, Halasa YA, Hall W, Haring D, Haro JM, Harrison JE, Havmoeller R, Hay RJ, Higashi H, Hill C, Hoen B, Hoffman H, Hotez PJ, Hoy D, Huang JJ, Ibeanusi SE, Jacobsen KH, James SL, Jarvis D, Jasrasaria R, Jayaraman S, Johns N, Jonas JB, Karthikeyan G, Kassebaum N, Kawakami N, Keren A, Khoo JP, King CH, Knowlton LM, Kobusingye O, Koranteng A, Krishnamurthi R, Lalloo R, Laslett LL, Lathlean T, Leasher JL, Lee YY, Leigh J, Lim SS, Limb E, Lin JK, Lipnick M, Lipshultz SE, Liu W, Loane M, Ohno SL, Lyons R, Ma J, Mabweijano J, MacIntyre MF, Malekzadeh R, Mallinger L, Manivannan S, Marcenes W, March L, Margolis DJ, Marks GB, Marks R, Matsumori A, Matzopoulos R, Mayosi BM, McAnulty JH, McDermott MM, McGill N, McGrath J, Medina-Mora ME, Meltzer M, Mensah GA, Merriman TR, Meyer AC, Miglioli V, Miller M, Miller TR, Mitchell PB, Mocumbi AO, Moffitt TE, Mokdad AA, Monasta L, Montico M, Moradi-Lakeh M, Moran A, Morawska L, Mori R, Murdoch ME, Mwaniki MK, Naidoo K, Nair MN, Naldi L, Narayan KM, Nelson PK, Nelson RG, Nevitt MC, Newton CR, Nolte S, Norman P, Norman R, O'Donnell M, O'Hanlon S, Olives C, Omer SB, Ortblad K, Osborne R, Ozgediz D, Page A, Pahari B, Pandian JD, Rivero AP, Patten SB, Pearce N, Padilla RP, Perez-Ruiz F, Perico N, Pesudovs K, Phillips D, Phillips MR, Pierce K, Pion S, Polanczyk GV, Polinder S, Pope CA, Popova S, Porrini E, Pourmalek F, Prince M, Pullan RL, Ramaiah KD, Ranganathan D, Razavi H, Regan M, Rehm JT, Rein DB, Remuzzi G, Richardson K, Rivara FP, Roberts T, Robinson C, De Leòn FR, Ronfani L, Room R, Rosenfeld LC, Rushton L, Sacco RL, Saha S, Sampson U, Sanchez-Riera L, Sanman E, Schwebel DC, Scott JG, Segui-Gomez M, Shahraz S, Shepard DS, Shin H, Shivakoti R, Singh D, Singh GM, Singh JA, Singleton J, Sleet DA, Sliwa K, Smith E, Smith JL, Stapelberg NJ, Steer A, Steiner T, Stolk WA, Stovner LJ, Sudfeld C, Syed S, Tamburlini G, Tavakkoli M, Taylor HR, Taylor JA, Taylor WJ, Thomas B, Thomson WM, Thurston GD, Tleyjeh IM, Tonelli M, Towbin JA, Truelsen T, Tsilimbaris MK, Ubeda C, Undurraga EA, van der Werf MJ, van Os J, Vavilala MS, Venketasubramanian N, Wang M, Wang W, Watt K, Weatherall DJ, Weinstock MA, Weintraub R, Weisskopf MG, Weissman MM, White RA, Whiteford H, Wiersma ST, Wilkinson JD, Williams HC, Williams SR, Witt E, Wolfe F, Woolf AD, Wulf S, Yeh PH, Zaidi AK, Zheng ZJ, Zonies D, Lopez AD, Murray CJ, AlMazroa MA, Memish ZA | display-authors = 6 | title = Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010 | journal = Lancet | volume = 380 | issue = 9859 | pages = 2163–2196 | date = December 2012 | pmid = 23245607 | pmc = 6350784 | doi = 10.1016/S0140-6736(12)61729-2 }} Some data indicate rates are roughly equal in women and men, but male excess in diabetes has been found in many populations with higher type 2 incidence, possibly due to sex-related differences in insulin sensitivity, consequences of obesity and regional body fat deposition, and other contributing factors such as high blood pressure, tobacco smoking, and alcohol intake.{{cite journal | vauthors = Gale EA, Gillespie KM | title = Diabetes and gender | journal = Diabetologia | volume = 44 | issue = 1 | pages = 3–15 | date = January 2001 | pmid = 11206408 | doi = 10.1007/s001250051573 | doi-access = free }}{{cite journal | vauthors = Meisinger C, Thorand B, Schneider A, Stieber J, Döring A, Löwel H | title = Sex differences in risk factors for incident type 2 diabetes mellitus: the MONICA Augsburg cohort study | journal = Archives of Internal Medicine | volume = 162 | issue = 1 | pages = 82–89 | date = January 2002 | pmid = 11784224 | doi = 10.1001/archinte.162.1.82 | doi-access = free }} [268] => [269] => The WHO estimates that diabetes resulted in 1.5 million deaths in 2012, making it the 8th leading cause of death.{{cite web |date=October 2013 |title=The top 10 causes of death Fact sheet N°310 |url=https://www.who.int/mediacentre/factsheets/fs310/en/ |url-status=live |archive-url=https://web.archive.org/web/20170530121727/http://www.who.int/mediacentre/factsheets/fs310/en/ |archive-date=30 May 2017 |publisher=World Health Organization}} However another 2.2 million deaths worldwide were attributable to high blood glucose and the increased risks of cardiovascular disease and other associated complications (e.g. kidney failure), which often lead to premature death and are often listed as the underlying cause on death certificates rather than diabetes.Public Health Agency of Canada, ''Diabetes in Canada: Facts and figures from a public health perspective''. Ottawa, 2011. For example, in 2017, the [[International Diabetes Federation]] (IDF) estimated that diabetes resulted in 4.0 million deaths worldwide, using modeling to estimate the total number of deaths that could be directly or indirectly attributed to diabetes. [270] => [271] => Diabetes occurs throughout the world but is more common (especially type 2) in more developed countries. The greatest increase in rates has however been seen in low- and middle-income countries, where more than 80% of diabetic deaths occur.{{cite journal | vauthors = Mathers CD, Loncar D | title = Projections of global mortality and burden of disease from 2002 to 2030 | journal = PLOS Medicine | volume = 3 | issue = 11 | pages = e442 | date = November 2006 | pmid = 17132052 | pmc = 1664601 | doi = 10.1371/journal.pmed.0030442 | doi-access = free }} The fastest prevalence increase is expected to occur in Asia and Africa, where most people with diabetes will probably live in 2030. The increase in rates in developing countries follows the trend of urbanization and lifestyle changes, including increasingly sedentary lifestyles, less physically demanding work and the global nutrition transition, marked by increased intake of foods that are high energy-dense but nutrient-poor (often high in sugar and saturated fats, sometimes referred to as the "Western-style" diet).{{cite journal | vauthors = Wild S, Roglic G, Green A, Sicree R, King H | title = Global prevalence of diabetes: estimates for the year 2000 and projections for 2030 | journal = Diabetes Care | volume = 27 | issue = 5 | pages = 1047–1053 | date = May 2004 | pmid = 15111519 | doi = 10.2337/diacare.27.5.1047 | doi-access = free }} The global number of diabetes cases might increase by 48% between 2017 and 2045. [272] => [273] => As of 2020, 38% of all US adults had prediabetes.{{cite web | title=Prevalence of Prediabetes Among Adults - Diabetes | website=CDC | date=2018-03-13 | url=https://www.cdc.gov/diabetes/data/statistics-report/prevalence-of-prediabetes.html | access-date=2022-12-15 | archive-date=2023-03-06 | archive-url=https://web.archive.org/web/20230306070935/https://www.cdc.gov/diabetes/data/statistics-report/prevalence-of-prediabetes.html | url-status=live }} [[Prediabetes]] is an early stage of diabetes. [274] => [275] => ==History== [276] => {{Main|History of diabetes}} [277] => Diabetes was one of the first diseases described,{{cite book| vauthors = Ripoll BC, Leutholtz I |title=Exercise and disease management|publisher=CRC Press|location=Boca Raton|isbn=978-1-4398-2759-8 |page=25 |url=https://books.google.com/books?id=eAn9-bm_pi8C&pg=PA25|edition=2nd|date=2011-04-25|url-status=live|archive-url=https://web.archive.org/web/20160403054841/https://books.google.com/books?id=eAn9-bm_pi8C&pg=PA25|archive-date=2016-04-03 }} with an [[Ancient Egypt|Egyptian]] manuscript from {{Abbr|c.|circa}} 1500 [[Common Era|BCE]] mentioning "too great emptying of the urine." The [[Ebers papyrus]] includes a recommendation for a drink to take in such cases.{{cite magazine|vauthors=Roberts J|title=Sickening sweet|magazine=Distillations|date=2015|volume=1|issue=4|pages=12–15|url=https://www.sciencehistory.org/distillations/magazine/sickening-sweet|access-date=20 March 2018|archive-date=13 November 2019|archive-url=https://web.archive.org/web/20191113141421/https://www.sciencehistory.org/distillations/magazine/sickening-sweet|url-status=live}} The first described cases are believed to have been type 1 diabetes.{{cite book | veditors = Poretsky L |title=Principles of diabetes mellitus|year=2009|publisher=Springer|location=New York|isbn=978-0-387-09840-1|page=3|url=https://books.google.com/books?id=i0qojvF1SpUC&pg=PA3 |edition=2nd |url-status=live |archive-url=https://web.archive.org/web/20160404170919/https://books.google.com/books?id=i0qojvF1SpUC&pg=PA3 |archive-date=2016-04-04}} Indian physicians around the same time identified the disease and classified it as ''madhumeha'' or "honey urine", noting the urine would attract ants. [278] => [279] => The term "diabetes" or "to pass through" was first used in 230 BCE by the Greek [[Apollonius (physician)|Apollonius of Memphis]]. The disease was considered rare during the time of the [[Roman empire]], with [[Galen]] commenting he had only seen two cases during his career. This is possibly due to the diet and lifestyle of the ancients, or because the clinical symptoms were observed during the advanced stage of the disease. Galen named the disease "diarrhea of the urine" (diarrhea urinosa). [280] => [281] => The earliest surviving work with a detailed reference to diabetes is that of [[Aretaeus of Cappadocia]] (2nd or early 3rd{{nbsp}}century CE). He described the symptoms and the course of the disease, which he attributed to the moisture and coldness, reflecting the beliefs of the "[[Pneumatic school|Pneumatic School]]". He hypothesized a correlation between diabetes and other diseases, and he discussed differential diagnosis from the snakebite, which also provokes excessive thirst. His work remained unknown in the West until 1552, when the first Latin edition was published in Venice.{{cite journal | vauthors = Laios K, Karamanou M, Saridaki Z, Androutsos G | title = Aretaeus of Cappadocia and the first description of diabetes | journal = Hormones | volume = 11 | issue = 1 | pages = 109–113 | year = 2012 | pmid = 22450352 | doi = 10.1007/BF03401545 | url = http://www.hormones.gr/pdf/HORMONES%202012,%20109-113.pdf | url-status = live | s2cid = 4730719 | archive-url = https://web.archive.org/web/20170104092212/http://www.hormones.gr/pdf/HORMONES%202012%2C%20109-113.pdf | archive-date = 2017-01-04 }} [282] => [283] => Two types of diabetes were identified as separate conditions for the first time by the Indian physicians [[Sushruta]] and [[Charaka]] in 400–500 CE with one type being associated with youth and another type with being overweight. Effective treatment was not developed until the early part of the 20th century when Canadians [[Frederick Banting]] and [[Charles Best (medical scientist)|Charles Best]] isolated and purified insulin in 1921 and 1922. This was followed by the development of the long-acting insulin [[NPH insulin|NPH]] in the 1940s. [284] => [285] => ===Etymology=== [286] => The word ''diabetes'' ({{IPAc-en|ˌ|d|aɪ|.|ə|ˈ|b|iː|t|iː|z}} or {{IPAc-en|ˌ|d|aɪ|.|ə|ˈ|b|iː|t|ᵻ|s}}) comes from [[Latin]] ''diabētēs'', which in turn comes from [[Ancient Greek]] [[wikt:διαβήτης|διαβήτης]] (''diabētēs''), which literally means "a passer through; a [[siphon]]".Oxford English Dictionary. ''diabetes''. Retrieved 2011-06-10. [[Ancient Greece|Ancient Greek]] [[physician]] [[Aretaeus of Cappadocia]] ([[Floruit|fl.]] 1st{{nbsp}}century [[Common Era|CE]]) used that word, with the intended meaning "excessive discharge of urine", as the name for the disease.{{cite web | vauthors = Harper D |title= Online Etymology Dictionary. ''diabetes.'' |year= 2001–2010 |url= http://www.etymonline.com/index.php?search=diabetes&searchmode=none |access-date= 2011-06-10 |url-status=live |archive-url= https://web.archive.org/web/20120113074242/http://www.etymonline.com/index.php?search=diabetes&searchmode=none |archive-date= 2012-01-13 }}Aretaeus, ''De causis et signis acutorum morborum (lib. 2)'', [https://www.perseus.tufts.edu/hopper/text?doc=Perseus:abo:tlg,0719,002:2:2&lang=original Κεφ. β. περὶ Διαβήτεω (Chapter 2, ''On Diabetes'', Greek original)] {{webarchive|url=https://web.archive.org/web/20140702232821/http://www.perseus.tufts.edu/hopper/text?doc=Perseus%3Aabo%3Atlg%2C0719%2C002%3A2%3A2&lang=original |date=2014-07-02 }}, on Perseus Ultimately, the word comes from Greek διαβαίνειν (''diabainein''), meaning "to pass through", which is composed of δια- (''dia''-), meaning "through" and βαίνειν (''bainein''), meaning "to go". The word "diabetes" is first recorded in English, in the form ''diabete'', in a medical text written around 1425. [287] => [288] => The word ''[[wikt:mellitus|mellitus]]'' ({{IPAc-en|m|ə|ˈ|l|aɪ|t|ə|s}} or {{IPAc-en|ˈ|m|ɛ|l|ᵻ|t|ə|s}}) comes from the classical Latin word ''mellītus'', meaning "mellite"Oxford English Dictionary. ''mellite''. Retrieved 2011-06-10. (i.e. sweetened with honey; honey-sweet{{cite web |title=MyEtimology. ''mellitus.'' |url=http://www.myetymology.com/latin/mellitus.html |access-date=2011-06-10 |url-status=usurped |archive-url =https://web.archive.org/web/20110316045914/http://www.myetymology.com/latin/mellitus.html |archive-date=2011-03-16 }}). The Latin word comes from ''mell''-, which comes from ''mel'', meaning "honey"; sweetness; pleasant thing, and the suffix -''ītus'', whose meaning is the same as that of the English suffix "-ite".Oxford English Dictionary. ''-ite''. Retrieved 2011-06-10. It was [[Thomas Willis]] who in 1675 added "mellitus" to the word "diabetes" as a designation for the disease, when he noticed the urine of a person with diabetes had a sweet taste (glycosuria). This sweet taste had been noticed in urine by the ancient Greeks, Chinese, Egyptians, Indians, and [[Persian people|Persians]] {{citation needed|date=April 2022}}. [289] => [290] => ==Society and culture== [291] => {{Further|List of films featuring diabetes}} [292] => [293] => The 1989 "[[St. Vincent Declaration]]"{{Cite book| vauthors = Tulchinsky TH, Varavikova EA |title=The New Public Health, Second Edition|publisher=[[Academic Press]]|year=2008|page=200|location=New York|isbn=978-0-12-370890-8}}{{cite journal | vauthors = Piwernetz K, Home PD, Snorgaard O, Antsiferov M, Staehr-Johansen K, Krans M | title = Monitoring the targets of the St Vincent Declaration and the implementation of quality management in diabetes care: the DIABCARE initiative. The DIABCARE Monitoring Group of the St Vincent Declaration Steering Committee | journal = Diabetic Medicine | volume = 10 | issue = 4 | pages = 371–377 | date = May 1993 | pmid = 8508624 | doi = 10.1111/j.1464-5491.1993.tb00083.x | s2cid = 9931183 }} was the result of international efforts to improve the care accorded to those with diabetes. Doing so is important not only in terms of quality of life and life expectancy but also economically{{snd}}expenses due to diabetes have been shown to be a major drain on health{{snd}}and productivity-related resources for healthcare systems and governments. [294] => [295] => Several countries established more and less successful national diabetes programmes to improve treatment of the disease.{{cite journal |vauthors=Dubois H, Bankauskaite V | title = Type 2 diabetes programmes in Europe | journal = Euro Observer | volume = 7 | issue = 2 | pages = 5–6 | year = 2005 | url = http://www2.lse.ac.uk/LSEHealthAndSocialCare/pdf/euroObserver/Obsvol7no2.pdf | url-status=live | archive-url = https://web.archive.org/web/20121024171754/http://www2.lse.ac.uk/LSEHealthAndSocialCare/pdf/euroObserver/Obsvol7no2.pdf | archive-date = 2012-10-24 }} [296] => [297] => === Diabetes stigma === [298] => Diabetes stigma describes the negative attitudes, judgment, discrimination, or prejudice against people with diabetes. Often, the stigma stems from the idea that diabetes (particularly Type 2 diabetes) resulted from poor lifestyle and unhealthy food choices rather than other causal factors like genetics and social determinants of health.{{Cite web |last=CDC |date=2022-11-03 |title=Diabetes Stigma: Learn About It, Recognize It, Reduce It |url=https://www.cdc.gov/diabetes/library/features/diabetes_stigma.html |access-date=2023-10-31 |website=Centers for Disease Control and Prevention |archive-date=2023-10-31 |archive-url=https://web.archive.org/web/20231031192432/https://www.cdc.gov/diabetes/library/features/diabetes_stigma.html |url-status=live }} Manifestation of stigma can be seen throughout different cultures and contexts. Scenarios include diabetes statuses affecting marriage proposals, workplace-employment, and social standing in communities.{{Cite journal |last1=Schabert |first1=Jasmin |last2=Browne |first2=Jessica L. |last3=Mosely |first3=Kylie |last4=Speight |first4=Jane |date=2013-03-01 |title=Social Stigma in Diabetes |journal=The Patient - Patient-Centered Outcomes Research |volume=6 |issue=1 |pages=1–10 |doi=10.1007/s40271-012-0001-0 |pmid=23322536 |s2cid=207490680 |issn=1178-1661|doi-access=free }} [299] => [300] => Stigma is also seen internally, as people with diabetes can also have negative beliefs about themselves. Often these cases of self-stigma are associated with higher diabetes-specific distress, lower self-efficacy, and poorer provider-patient interactions during diabetes care.{{Cite journal |last1=Puhl |first1=Rebecca M. |last2=Himmelstein |first2=Mary S. |last3=Hateley-Browne |first3=Jessica L. |last4=Speight |first4=Jane |date=October 2020 |title=Weight stigma and diabetes stigma in U.S. adults with type 2 diabetes: Associations with diabetes self-care behaviors and perceptions of health care |url=https://doi.org/10.1016/j.diabres.2020.108387 |journal=Diabetes Research and Clinical Practice |volume=168 |pages=108387 |doi=10.1016/j.diabres.2020.108387 |pmid=32858100 |s2cid=221366068 |issn=0168-8227}} [301] => [302] => === Racial and economic inequalities === [303] => Racial and ethnic minorities are disproportionately affected with higher prevalence of diabetes compared to non-minority individuals.{{Cite journal |last1=Spanakis |first1=Elias K. |last2=Golden |first2=Sherita Hill |date=December 2013 |title=Race/Ethnic Difference in Diabetes and Diabetic Complications |journal=Current Diabetes Reports |volume=13 |issue=6 |pages=10.1007/s11892–013–0421–9 |doi=10.1007/s11892-013-0421-9 |issn=1534-4827 |pmc=3830901 |pmid=24037313}} While US adults overall have a 40% chance of developing type 2 diabetes, Hispanic/Latino adults chance is more than 50%.{{Cite web |last=CDC |date=2022-04-04 |title=Hispanic/Latino Americans and Type 2 Diabetes |url=https://www.cdc.gov/diabetes/library/features/hispanic-diabetes.html |access-date=2023-10-31 |website=Centers for Disease Control and Prevention |archive-date=2023-10-31 |archive-url=https://web.archive.org/web/20231031192358/https://www.cdc.gov/diabetes/library/features/hispanic-diabetes.html |url-status=live }} African Americans also are much more likely to be diagnosed with diabetes compared to White Americans. Asians have increased risk of diabetes as diabetes can develop at lower BMI due to differences in visceral fat compared to other races. For Asians, diabetes can develop at a younger age and lower body fat compared to other groups. Additionally, diabetes is highly underreported in Asian American people, as 1 in 3 cases are diagnosed compared to the average 1 in 5 for the nation.{{Cite web |last=CDC |date=2022-11-21 |title=Diabetes and Asian American People |url=https://www.cdc.gov/diabetes/library/spotlights/diabetes-asian-americans.html |access-date=2023-10-31 |website=Centers for Disease Control and Prevention |archive-date=2023-10-31 |archive-url=https://web.archive.org/web/20231031192358/https://www.cdc.gov/diabetes/library/spotlights/diabetes-asian-americans.html |url-status=live }} [304] => [305] => People with diabetes who have neuropathic symptoms such as numbness or tingling in feet or hands are twice as likely to be [[unemployed]] as those without the symptoms.{{cite journal | vauthors = Stewart WF, Ricci JA, Chee E, Hirsch AG, Brandenburg NA | title = Lost productive time and costs due to diabetes and diabetic neuropathic pain in the US workforce | journal = Journal of Occupational and Environmental Medicine | volume = 49 | issue = 6 | pages = 672–679 | date = June 2007 | pmid = 17563611 | doi = 10.1097/JOM.0b013e318065b83a | s2cid = 21487348 }} [306] => [307] => In 2010, diabetes-related emergency room (ER) visit rates in the United States were higher among people from the lowest income communities (526 per 10,000 population) than from the highest income communities (236 per 10,000 population). Approximately 9.4% of diabetes-related ER visits were for the uninsured.{{cite journal |author1=Washington R.E. |author2=Andrews R.M. |author3=Mutter R.L. |title=Emergency Department Visits for Adults with Diabetes, 2010 |date=November 2013 |website=HCUP Statistical Brief #167 |publisher=Agency for Healthcare Research and Quality |url=http://www.hcup-us.ahrq.gov/reports/statbriefs/sb167.jsp |location=Rockville MD |pmid=24455787 |url-status=live |archive-url=https://web.archive.org/web/20131203011036/http://www.hcup-us.ahrq.gov/reports/statbriefs/sb167.jsp |archive-date=2013-12-03 }} [308] => [309] => ===Naming=== [310] => The term "type 1 diabetes" has replaced several former terms, including childhood-onset diabetes, juvenile diabetes, and insulin-dependent diabetes mellitus. Likewise, the term "type 2 diabetes" has replaced several former terms, including adult-onset diabetes, obesity-related diabetes, and noninsulin-dependent diabetes mellitus. Beyond these two types, there is no agreed-upon standard nomenclature.{{Cite web|title=Type 1 vs. Type 2 Diabetes Differences: Which One Is Worse?|url=https://www.medicinenet.com/type_1_vs_type_2_diabetes_similarities_differences/article.htm|access-date=2021-03-21|website=MedicineNet|archive-date=2021-04-14|archive-url=https://web.archive.org/web/20210414120708/https://www.medicinenet.com/type_1_vs_type_2_diabetes_similarities_differences/article.htm|url-status=live}} [311] => [312] => Diabetes mellitus is also occasionally known as "sugar diabetes" to differentiate it from [[diabetes insipidus]].{{cite book| vauthors = Parker K |title= Living with diabetes|date=2008|publisher=Facts On File|location=New York|isbn=978-1-4381-2108-6|page=[https://archive.org/details/livingwithdiabet0000park/page/143 143]|url=https://archive.org/details/livingwithdiabet0000park|url-access=registration}} [313] => [314] => ==Other animals== [315] => {{main|Diabetes in dogs|Diabetes in cats}} [316] => [317] => Diabetes can occur in mammals or reptiles.{{cite journal | vauthors = Niaz K, Maqbool F, Khan F, Hassan FI, Momtaz S, Abdollahi M | title = Comparative occurrence of diabetes in canine, feline, and few wild animals and their association with pancreatic diseases and ketoacidosis with therapeutic approach | journal = Veterinary World | volume = 11 | issue = 4 | pages = 410–422 | date = April 2018 | pmid = 29805204 | pmc = 5960778 | doi = 10.14202/vetworld.2018.410-422 }}{{cite book | vauthors = Stahl SJ | chapter =Hyperglycemia in Reptiles |date=2006-01-01 | title = Reptile Medicine and Surgery | edition = Second |pages=822–830 | veditors = Mader DR |place=Saint Louis |publisher=W.B. Saunders |doi=10.1016/b0-72-169327-x/50062-6 |isbn=978-0-7216-9327-9 }} Birds do not develop diabetes because of their unusually high tolerance for elevated blood glucose levels.{{cite journal | vauthors = Sweazea KL | title = Revisiting glucose regulation in birds - A negative model of diabetes complications | journal = Comparative Biochemistry and Physiology. Part B, Biochemistry & Molecular Biology | volume = 262 | pages = 110778 | date = 8 July 2022 | pmid = 35817273 | doi = 10.1016/j.cbpb.2022.110778 | s2cid = 250404382 }} [318] => [319] => In animals, diabetes is most commonly encountered in dogs and cats. Middle-aged animals are most commonly affected. Female dogs are twice as likely to be affected as males, while according to some sources, male cats are more prone than females. In both species, all breeds may be affected, but some small dog breeds are particularly likely to develop diabetes, such as [[Poodle|Miniature Poodles]].{{cite web | title=Diabetes mellitus | website= Merck Veterinary Manual | edition = 9th | url=http://www.merckvetmanual.com/mvm/index.jsp?cfile=htm/bc/40302.htm | year=2005 | access-date=2011-10-23 | url-status=live | archive-url=https://web.archive.org/web/20110927154816/http://www.merckvetmanual.com/mvm/index.jsp?cfile=htm%2Fbc%2F40302.htm | archive-date=2011-09-27 }} [320] => [321] => Feline diabetes is strikingly similar to human type 2 diabetes. The [[Burmese cat|Burmese]], [[Russian Blue]], [[Abyssinian cat|Abyssinian]], and [[Norwegian Forest cat|Norwegian Forest]] cat breeds are at higher risk than other breeds. Overweight cats are also at higher risk.{{cite book|vauthors=Öhlund M|title=Feline diabetes mellitus Aspects on epidemiology and pathogenesis|publisher=Acta Universitatis agriculturae Sueciae|isbn=978-91-7760-067-1|url=https://pub.epsilon.slu.se/14746/1/ohlund_m_171123.pdf|access-date=2017-12-18|archive-date=2021-04-13|archive-url=https://web.archive.org/web/20210413223918/https://pub.epsilon.slu.se/14746/1/ohlund_m_171123.pdf|url-status=live}} [322] => [323] => The symptoms may relate to fluid loss and polyuria, but the course may also be insidious. Diabetic animals are more prone to infections. The long-term complications recognized in humans are much rarer in animals. The principles of treatment (weight loss, oral antidiabetics, subcutaneous insulin) and management of emergencies (e.g. ketoacidosis) are similar to those in humans. [324] => [325] => == See also == [326] => * [[Outline of diabetes]] [327] => [328] => == References == [329] => {{Reflist}} [330] => [331] => == External links == [332] => {{Sister project links|display=Diabetes mellitus}} [333] => [334] => * [https://www.diabetes.org American Diabetes Association] [335] => * [https://diabetesatlas.org/ IDF Diabetes Atlas] [336] => * [https://www.nei.nih.gov/learn-about-eye-health/resources-for-health-educators/national-eye-health-education-program/nehep-partnership-directory/national-diabetes-education-program National Diabetes Education Program] [337] => * [https://diabetesjournals.org/care/issue/42/Supplement_1 ADA's Standards of Medical Care in Diabetes 2019] [338] => * {{cite journal | vauthors = Polonsky KS | title = The past 200 years in diabetes | journal = The New England Journal of Medicine | volume = 367 | issue = 14 | pages = 1332–1340 | date = October 2012 | pmid = 23034021 | doi = 10.1056/NEJMra1110560 | s2cid = 9456681 | doi-access = free }} [339] => * {{cite web | url = https://medlineplus.gov/diabetes.html | publisher = U.S. National Library of Medicine | work = MedlinePlus | title = Diabetes }} [340] => [341] => {{Medical condition classification and resources [342] => | ICD10={{ICD10|E|10||e|10}}–{{ICD10|E|14||e|10}} [343] => | ICD9={{ICD9|250}} [344] => | MedlinePlus=001214 [345] => | eMedicineSubj=med [346] => | eMedicineTopic=546 [347] => | eMedicine_mult={{eMedicine2|emerg|134}} [348] => | MeSH=D003920| [349] => }} [350] => {{Diabetes}} [351] => {{Disease of the pancreas and glucose metabolism}} [352] => {{Authority control}} [353] => [354] => {{DEFAULTSORT:Diabetes Mellitus}} [355] => [[Category:Diabetes| ]] [356] => [[Category:Endocrine diseases]] [357] => [[Category:Metabolic disorders]] [358] => [[Category:Wikipedia emergency medicine articles ready to translate]] [359] => [[Category:Wikipedia medicine articles ready to translate]] [] => )
good wiki

Diabetes

Diabetes is a chronic metabolic disorder characterized by high levels of glucose (sugar) in the blood. It occurs due to the body's inability to produce enough insulin or use it effectively.

More about us

About

It occurs due to the body's inability to produce enough insulin or use it effectively. This condition affects people of all ages and can lead to various complications if not managed properly. The Wikipedia page on diabetes provides comprehensive information about the disease, including its types, causes, symptoms, diagnosis, treatment, and prevention strategies. It explains that there are different types of diabetes, with type 1 and type 2 being the most common. Type 1 diabetes is an autoimmune condition where the immune system attacks and destroys the insulin-producing cells in the pancreas. Type 2 diabetes occurs when the body becomes resistant to insulin or does not produce enough of it. Other forms of diabetes include gestational diabetes, which occurs during pregnancy, and rare genetic forms. The page describes the risk factors that increase the likelihood of developing diabetes, such as family history, obesity, a sedentary lifestyle, and certain underlying health conditions. It also discusses the symptoms associated with diabetes, which may include increased thirst and urination, unexplained weight loss, fatigue, and blurred vision. The diagnosis and monitoring of diabetes involve various tests, such as measuring blood glucose levels, conducting an oral glucose tolerance test, and assessing hemoglobin A1c levels. The page explains the importance of early detection and regular monitoring to prevent complications. Treatment options for diabetes commonly include lifestyle modifications, such as maintaining a healthy diet and engaging in regular physical activity. Additionally, medication, including insulin injections, may be prescribed to control blood sugar levels. The page highlights the importance of self-management and the involvement of healthcare professionals in diabetes care. Furthermore, the page addresses complications associated with diabetes, such as heart disease, stroke, kidney disease, nerve damage, and eye problems. It stresses the significance of managing blood sugar levels, cholesterol, and blood pressure to reduce the risk of these complications. Lastly, the Wikipedia page provides insights into the prevention of diabetes. It emphasizes the significance of healthy lifestyle choices, including weight management, regular exercise, and a balanced diet. The page also mentions ongoing research efforts in finding a cure for diabetes and improving treatment options. Overall, the Wikipedia page on diabetes offers a comprehensive overview of the disease, covering its various aspects, from causes and symptoms to diagnosis, treatment, and prevention. It serves as a valuable resource for individuals seeking information about diabetes and for healthcare professionals involved in its management.

Expert Team

Vivamus eget neque lacus. Pellentesque egauris ex.

Award winning agency

Lorem ipsum, dolor sit amet consectetur elitorceat .

10 Year Exp.

Pellen tesque eget, mauris lorem iupsum neque lacus.

You might be interested in